[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Westmed, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":178},{"warningLetters":4,"total":177},[5,32,56,78,99,120,138,159],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":11,"recipient_name":29,"body_fetched_at":30,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},3480,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2021-03-05T17:30:00Z\">03\u002F05\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-04T05:00:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwestminster-international-ltd-613566-03042021\">Westminster International Ltd\u003C\u002Fa>","Center for Devices and Radiological Health","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwestminster-international-ltd-613566-03252025\">\u003Ctime datetime=\"2025-03-31T04:00:00Z\">03\u002F31\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Roger William Worrall\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Westminster International Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Westminster House, Blacklocks Hill (Banbury Lane)\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Banbury, Oxfordshire\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>OX17 2BS\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:r.worrall@wg-plc.com\"> r.worrall@wg-plc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>WARNING LETTER\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>RE: &nbsp;&nbsp;&nbsp;&nbsp;Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fwww.wi-ltd.com\u002F and https:\u002F\u002Fwww.wg-plc.com\u002F on February 25, 2021. The FDA has observed that your website offers products for measuring human body temperature, specifically the “WG 520” and “WG 620”, for sale in the United States. Based on our review, these products are intended to mitigate, prevent, treat, diagnose or cure COVID-19\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa> in people, and thus are devices under section 201(h) of the Federal, Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA’s review of your website revealed the following statements that establish that the WG 520 and WG 620 are intended for the mitigation, prevention, treatment, diagnosis, or cure\u003Ca>\u003C\u002Fa> of COVID-19, including:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The WG 520 and WG 620 can be found under the “Coronavirus” tab on the main webpage, which leads to a webpage titled, “Thermal Cameras, Coronavirus &amp; Fever Detection Products” [Published on the firm’s webpage, https:\u002F\u002Fwww.wi-ltd.com\u002Fcoronavirus\u002F] \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The firm refers to the WG 520 and WG 620 as “WG 520 Fever, Coronavirus Covid-19, Flu, Ebola Screening System” and “WG 620 Fever, Coronavirus Covid-19, Flu, Ebola Detection Camera” respectively. [Published on the “Thermal Cameras, Mass Fever Detection - Coronavirus Covid-19, Ebola etc” webpage, https:\u002F\u002Fwww.wi-ltd.com\u002Fsolution\u002Ffever-detection-systems\u002F] \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“The system was designed by medical professionals to be used as a first level mass screening test for identifying individuals that have an above normal body temperature and may be suffering from Coronavirus, Ebola, Common Influenza, SARS and other flu variants such as Avian Flu, Bird and Swine flu.” [Published in WG 520 brochure, https:\u002F\u002Fwww.wi-ltd.com\u002Fwp-content\u002Fuploads\u002F2016\u002F06\u002FWG-520-Fever-Coronavirus-Covid-19-Flu-Ebola-Screening-System-12.pdf] \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“The system was designed by thermal imaging professionals in Europe to be used as a first level mass screening test for identifying individuals that have an above normal body temperature and may be suffering from Coronavirus, Ebola, Common Influenza, SARS and other flu variants.” [Published in the WG 620 brochure, https:\u002F\u002Fwww.wi-ltd.com\u002Fwp-content\u002Fuploads\u002F2020\u002F04\u002FWG-620-Fever-Detection-Camera-2.pdf] \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The WG 520 and WG 620 are\u003C\u002Fspan>\u003Cspan> offered for sale\u003C\u002Fspan>\u003Cspan> in the United States without marketing approval, clearance, or authorization from FDA. &nbsp;Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. §&nbsp;351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these products into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>[\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>]\u003C\u002Fsup> In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19\u003C\u002Fspan>\u003Cspan>.\u003Csup>[\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[3]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>]\u003C\u002Fsup> \u003C\u002Fspan>\u003Cspan>Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you offer for sale products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Use of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment.&nbsp; These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fwww.wi-ltd.com\u002F, includes statements that indicate that the WG 520 and WG 620 are intended to scan multiple individuals simultaneously, including:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Moving Crowd Screening Capability” [Published in WG 520 brochure, https:\u002F\u002Fwww.wi-ltd.com\u002Fwp-content\u002Fuploads\u002F2016\u002F06\u002FWG-520-Fever-Coronavirus-Covid-19-Flu-Ebola-Screening-System-12.pdf] \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Detects up to 5 People at the Same Time”, “The WG 620 Fever Detection Camera enables accurate and fast fever screening of multiple individuals at once”, and “No operator is required for operation and the device can measure up to 5 people at the same time within a range of 2 metres.” [These three statements published in the WG 620 brochure, https:\u002F\u002Fwww.wi-ltd.com\u002Fwp-content\u002Fuploads\u002F2020\u002F04\u002FWG-620-Fever-Detection-Camera-2.pdf] \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>For more information \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>about FDA’s regulation of\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan> devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, \u003Cspan>visit our website at\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">\u003Cspan>\u003Cspan>https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>\u003Cspan>. In addition, the guidance titled “Enforcement Policy for Telethermographic Systems During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency”\u003Csup>[\u003C\u002Fsup>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[4]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Csup>\u003Cspan>\u003Cspan>\u003Cspan>]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fsup>\u003Cspan>\u003Cspan>\u003Cspan> provides information about FDA’s \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>policies intended to help expand the availability of telethermographic systems used for body temperature measurements for triage use during the COVID-19 public health emergency. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should take action to address the\u003C\u002Fspan>\u003Cspan> violations\u003C\u002Fspan>\u003Cspan> cited in this letter\u003C\u002Fspan>\u003Cspan>. \u003C\u002Fspan>\u003Cspan>This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that misbrand the products in violation of the Act. \u003Cb>Within 48 hours, please send an email to \u003C\u002Fb>\u003C\u002Fspan>\u003Ca href=\"mailto:COVID-19-Task-Force-CDRH@fda.hhs.gov\">\u003Cb>\u003Cspan>COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fa>\u003Cb> \u003C\u002Fb>\u003Cspan>\u003Cspan>describing the specific steps you have taken to address these\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>\u003Cspan>violations, using CMS # 613566 as reference\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>. \u003Cspan>Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>Failure to \u003C\u002Fspan>\u003Cspan>adequately \u003C\u002Fspan>\u003Cspan>prevent \u003C\u002Fspan>\u003Cspan>address any\u003C\u002Fspan>\u003Cspan> violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.&nbsp;Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act.&nbsp;This list can be found at \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">\u003Cspan>https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>Once you have taken actions to&nbsp;\u003C\u002Fspan>\u003Cspan>address\u003C\u002Fspan>\u003Cspan> the sale of \u003C\u002Fspan>\u003Cspan>unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, \u003C\u002Fspan>\u003Cspan>and \u003C\u002Fspan>\u003Cspan>such\u003C\u002Fspan>\u003Cspan> actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken \u003C\u002Fspan>\u003Cspan>appropriate\u003C\u002Fspan>\u003Cspan> corrective \u003C\u002Fspan>\u003Cspan>action.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This letter notifies you of our concerns and provides you with an opportunity to address them. \u003C\u002Fspan>\u003Cspan>\u003Cspan>If you cannot \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>take action to address this matter \u003C\u002Fspan>\u003Cspan>\u003Cspan>completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>If you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please direct any inquiries to FDA at \u003C\u002Fspan>\u003Ca href=\"mailto:COVID-19-Task-Force-CDRH@fda.hhs.gov\">\u003Cspan>COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Courtney H. Lias, Ph.D.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Acting Office Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>OHT3: Office of GastroRenal, ObGyn,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>General Hospital and Urology Devices\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Product Evaluation and Quality\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Devices and Radiological Health\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cdiv>&nbsp;\n\u003Chr>\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Csup>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fsup>\u003Cspan>&nbsp;As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Csup>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fsup>\u003Cspan>&nbsp;Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), \u003Ci>available at\u003C\u002Fi> \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">\u003Cspan>https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Csup>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[3]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fsup>\u003Cspan>&nbsp;President Donald J. Trump, Proclamation\u003C\u002Fspan>\u003Cspan> on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19\u003C\u002Fspan>\u003Cspan>) Outbreak (\u003C\u002Fspan>\u003Cspan>Mar. 13, 2020\u003C\u002Fspan>\u003Cspan>), \u003Ci>available at\u003C\u002Fi> \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">\u003Cspan>https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Csup>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[4]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fsup>&nbsp;\u003Cspan>Accessible\u003Ci> \u003C\u002Fi>at \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F137079\u002Fdownload\">\u003Cspan>https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F137079\u002Fdownload\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Chr>\n\u003Cdiv>\n\u003Cdiv>\u003Ca>\u003C\u002Fa>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>&nbsp;\u003Ca>[LJ1]\u003C\u002Fa>&nbsp;\u003Ca>[LJ1]\u003C\u002Fa>\u003C\u002Fspan>Only email we could find. Person’s title is “Secretary”\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRoger William Worrall\n\nWestminster International Ltd\n\nWestminster House, Blacklocks Hill (Banbury Lane)\n\nBanbury, Oxfordshire\n\nOX17 2BS\n\nUnited Kingdom\n\nr.worrall@wg-plc.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your websites at the Internet addresses https:\u002F\u002Fwww.wi-ltd.com\u002F and https:\u002F\u002Fwww.wg-plc.com\u002F on February 25, 2021. The FDA has observed that your website offers products for measuring human body temperature, specifically the “WG 520” and “WG 620”, for sale in the United States. Based on our review, these products are intended to mitigate, prevent, treat, diagnose or cure COVID-19[1] in people, and thus are devices under section 201(h) of the Federal, Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nFDA’s review of your website revealed the following statements that establish that the WG 520 and WG 620 are intended for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, including:\n\nThe WG 520 and WG 620 can be found under the “Coronavirus” tab on the main webpage, which leads to a webpage titled, “Thermal Cameras, Coronavirus & Fever Detection Products” [Published on the firm’s webpage, https:\u002F\u002Fwww.wi-ltd.com\u002Fcoronavirus\u002F]\n\nThe firm refers to the WG 520 and WG 620 as “WG 520 Fever, Coronavirus Covid-19, Flu, Ebola Screening System” and “WG 620 Fever, Coronavirus Covid-19, Flu, Ebola Detection Camera” respectively. [Published on the “Thermal Cameras, Mass Fever Detection - Coronavirus Covid-19, Ebola etc” webpage, https:\u002F\u002Fwww.wi-ltd.com\u002Fsolution\u002Ffever-detection-systems\u002F]\n\n“The system was designed by medical professionals to be used as a first level mass screening test for identifying individuals that have an above normal body temperature and may be suffering from Coronavirus, Ebola, Common Influenza, SARS and other flu variants such as Avian Flu, Bird and Swine flu.” [Published in WG 520 brochure, https:\u002F\u002Fwww.wi-ltd.com\u002Fwp-content\u002Fuploads\u002F2016\u002F06\u002FWG-520-Fever-Coronavirus-Covid-19-Flu-Ebola-Screening-System-12.pdf]\n\n“The system was designed by thermal imaging professionals in Europe to be used as a first level mass screening test for identifying individuals that have an above normal body temperature and may be suffering from Coronavirus, Ebola, Common Influenza, SARS and other flu variants.” [Published in the WG 620 brochure, https:\u002F\u002Fwww.wi-ltd.com\u002Fwp-content\u002Fuploads\u002F2020\u002F04\u002FWG-620-Fever-Detection-Camera-2.pdf]\n\nThe WG 520 and WG 620 are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these products into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.[[2]] In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.[[3]] Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you offer for sale products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nUse of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fwww.wi-ltd.com\u002F, includes statements that indicate that the WG 520 and WG 620 are intended to scan multiple individuals simultaneously, including:\n\n“Moving Crowd Screening Capability” [Published in WG 520 brochure, https:\u002F\u002Fwww.wi-ltd.com\u002Fwp-content\u002Fuploads\u002F2016\u002F06\u002FWG-520-Fever-Coronavirus-Covid-19-Flu-Ebola-Screening-System-12.pdf]\n\n“Detects up to 5 People at the Same Time”, “The WG 620 Fever Detection Camera enables accurate and fast fever screening of multiple individuals at once”, and “No operator is required for operation and the device can measure up to 5 people at the same time within a range of 2 metres.” [These three statements published in the WG 620 brochure, https:\u002F\u002Fwww.wi-ltd.com\u002Fwp-content\u002Fuploads\u002F2020\u002F04\u002FWG-620-Fever-Detection-Camera-2.pdf]\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Enforcement Policy for Telethermographic Systems During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency”[[4]] provides information about FDA’s policies intended to help expand the availability of telethermographic systems used for body temperature measurements for triage use during the COVID-19 public health emergency.\n\nYou should take action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations, using CMS # 613566 as reference. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately prevent address any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and such actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken appropriate corrective action.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nActing Office Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n[1] As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n[2] Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n[3] President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n[4] Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F137079\u002Fdownload.\n\n[LJ1] [LJ1]Only email we could find. Person’s title is “Secretary”","Westminster International Ltd","westminster-international-ltd-613566-03042021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwestminster-international-ltd-613566-03042021","2026-10-26T08:10:31.276831+00:00","Warning Letter","Closed Out","2021-03-05","613566","Medical Devices","2025-03-31","Roger William Worrall","2026-08-20T03:18:32.483+00:00","2021-03-04",{"id":33,"raw":34,"subject":40,"body_html":41,"body_text":42,"firm_name":43,"letter_id":44,"created_at":45,"fei_number":20,"letter_url":46,"updated_at":47,"action_type":23,"case_status":48,"posted_date":49,"marcs_cms_no":50,"product_type":51,"closeout_date":20,"issuing_office":38,"recipient_name":52,"body_fetched_at":53,"delivery_method":54,"recipient_title":20,"reference_number":20,"action_taken_date":55,"medical_device_id":20,"response_letter_date":20},1084,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2025-01-21T14:20:00Z\">01\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-13T05:00:00Z\">11\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwestern-innovations-inc-679737-11132024\">Western Innovations, Inc.\u003C\u002Fa>","Human Foods Program","CGMP\u002FDietary Supplement\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FDietary Supplement\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>SJ Jernigan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Western Innovations, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4825 Nome St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Denver\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80239\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jerry@westerninnovationsinc.com\"> jerry@westerninnovationsinc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 13, 2024\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #679737\u003C\u002Fp>\u003Cp>Dear Mr. Jernigan:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 4825 Nome Street, Denver, CO, from January 29 through February 21, 2024. Based on inspectional findings, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on February 21, 2024, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated February 22 and 23, March 12, 26, and 29, and April 4 and 8, 2024, and we address your responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility on January 29 through February 21, 2024, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplements manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1. You failed to establish component specifications for each component that you used in the manufacture of your Acetyl-glutathione dietary supplement product, as required by 21 CFR 111.70(b).\u003C\u002Fp>\u003Cp>• You failed to establish an identity specification, as required by 21 CFR 111.70(b)(1). Specifically, in your February 22, 2024, response, you provided a Certificate of Analysis (CoA) for the component silica mineral hydride complex from your supplier HWH World. The methods listed on the CoA do not provide the specificity necessary for proper identification of this dietary ingredient. Furthermore, you provided CoAs from your suppliers for the silica mineral hydride complex component and the magnesium ascorbate component; however, it is unclear whether these specifications are intended to suffice as your firm’s specifications and if they have been approved by your firm’s quality control personnel.\u003Cbr>• You failed to establish component specifications that are necessary to ensure that specifications for the purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically, you provided a CoA for your silica mineral hydride complex component from your supplier HWH World that is lacking strength specifications. Your finished product labeling for your Acetyl-glutathione product lists this component as being composed of enhanced silica with potassium carbonate, potassium citrate hydroxide, and magnesium sulfate.\u003Cbr>• You failed to establish limits on those types of contamination that may adulterate or that may lead to adulteration of the finished batch of the dietary supplement to ensure the quality of the dietary supplement for your Acetyl-glutathione component, as required by 21 CFR 111.70(b)(3). Specifically, you did not provide any heavy metal or microbial test specifications for your Acetyl-glutathione component.\u003C\u002Fp>\u003Cp>2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required 21 CFR 111.103. Specifically, you have not established written procedures for quality control operations. This violation was not addressed in any of your responses to Form FDA 483.\u003C\u002Fp>\u003Cp>3. You failed to prepare and follow a written master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). The MMRs must include the required elements of 21 CFR 111.210. Specifically, the MMR you provided in your April 8, 2024, response, which you call an “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” or “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” is not specific to a unique formulation of a dietary supplement and is not specific to batch size.\u003C\u002Fp>\u003Cp>4. Your batch production records failed to include complete information relating to the production and control of each batch, as required by 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, your batch production records failed to include:\u003C\u002Fp>\u003Cp>• A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing (21 CFR 111.260(f));\u003Cbr>• The actual results obtained during any monitoring operation (21 CFR 111.260(g));\u003Cbr>• The results of any testing or examination performed during the batch production, or a cross-reference to such results (21 CFR 111.260(h));\u003Cbr>• Documentation, at the date and time of performance, of labeling operations (21 CFR 111.260(k));\u003Cbr>• An actual or representative label, or a cross-reference to the physical location of the actual or representative label used in production (21 CFR 111.260(k)(2)).\u003C\u002Fp>\u003Cp>These violations were not addressed in any of your responses to Form FDA 483.\u003C\u002Fp>\u003Cp>5. You failed to establish and follow written procedures for returned dietary supplements, as required by 21 CFR 111.503. Specifically, your SOP for returned dietary supplements does not include all required information. Your response dated April 8, 2024, includes a document titled Returned Product Procedure. However, the procedure does not address the requirement for quality control to conduct a material review and make a disposition decision, as required by 21 CFR 111.510. The procedure states that the food safety officer will perform these activities. Furthermore, the procedure also does not address the requirement that if the reason for a dietary supplement being returned implicates other batches, you must conduct an investigation of the manufacturing processes and each of those other batches to determine compliance with specifications, as required by 21 CFR 111.530.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take prompt action to address the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>In addition to the above-mentioned violations, we also have the following comment:\u003C\u002Fp>\u003Cp>1. Your current finished product specification sheet for your Acetyl-glutathione product lists the test method as N\u002FA. Please update this document to include the UPLC test method that is used to test the identity, purity, and strength of the finished product.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be addressed to Rebecca Allen, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #679737 on any submissions and within the subject line of any emails\u003Ca> to us.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>Sincerely,&nbsp;&nbsp;\u003Cbr>\u002FS\u002F&nbsp;\u003Cbr>Maria S. Knirk, JD MBA&nbsp;\u003Cbr>Acting Director, Office of Enforcement&nbsp;&nbsp;\u003Cbr>Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nSJ Jernigan\n\nRecipient Title\n\nCEO\n\nWestern Innovations, Inc.\n\n4825 Nome St\n\nDenver, CO 80239\n\nUnited States\n\njerry@westerninnovationsinc.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nNovember 13, 2024\nWARNING LETTER\nCMS #679737\nDear Mr. Jernigan:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 4825 Nome Street, Denver, CO, from January 29 through February 21, 2024. Based on inspectional findings, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on February 21, 2024, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated February 22 and 23, March 12, 26, and 29, and April 4 and 8, 2024, and we address your responses below.\nAdulterated Dietary Supplements\nThe inspection of your facility on January 29 through February 21, 2024, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplements manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. § 342(g)(1)] in that they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\nYour significant violations of the CGMP requirements are as follows:\n1. You failed to establish component specifications for each component that you used in the manufacture of your Acetyl-glutathione dietary supplement product, as required by 21 CFR 111.70(b).\n• You failed to establish an identity specification, as required by 21 CFR 111.70(b)(1). Specifically, in your February 22, 2024, response, you provided a Certificate of Analysis (CoA) for the component silica mineral hydride complex from your supplier HWH World. The methods listed on the CoA do not provide the specificity necessary for proper identification of this dietary ingredient. Furthermore, you provided CoAs from your suppliers for the silica mineral hydride complex component and the magnesium ascorbate component; however, it is unclear whether these specifications are intended to suffice as your firm’s specifications and if they have been approved by your firm’s quality control personnel.\n• You failed to establish component specifications that are necessary to ensure that specifications for the purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically, you provided a CoA for your silica mineral hydride complex component from your supplier HWH World that is lacking strength specifications. Your finished product labeling for your Acetyl-glutathione product lists this component as being composed of enhanced silica with potassium carbonate, potassium citrate hydroxide, and magnesium sulfate.\n• You failed to establish limits on those types of contamination that may adulterate or that may lead to adulteration of the finished batch of the dietary supplement to ensure the quality of the dietary supplement for your Acetyl-glutathione component, as required by 21 CFR 111.70(b)(3). Specifically, you did not provide any heavy metal or microbial test specifications for your Acetyl-glutathione component.\n2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required 21 CFR 111.103. Specifically, you have not established written procedures for quality control operations. This violation was not addressed in any of your responses to Form FDA 483.\n3. You failed to prepare and follow a written master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). The MMRs must include the required elements of 21 CFR 111.210. Specifically, the MMR you provided in your April 8, 2024, response, which you call an “(b)(4)” or “(b)(4),” is not specific to a unique formulation of a dietary supplement and is not specific to batch size.\n4. Your batch production records failed to include complete information relating to the production and control of each batch, as required by 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, your batch production records failed to include:\n• A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing (21 CFR 111.260(f));\n• The actual results obtained during any monitoring operation (21 CFR 111.260(g));\n• The results of any testing or examination performed during the batch production, or a cross-reference to such results (21 CFR 111.260(h));\n• Documentation, at the date and time of performance, of labeling operations (21 CFR 111.260(k));\n• An actual or representative label, or a cross-reference to the physical location of the actual or representative label used in production (21 CFR 111.260(k)(2)).\nThese violations were not addressed in any of your responses to Form FDA 483.\n5. You failed to establish and follow written procedures for returned dietary supplements, as required by 21 CFR 111.503. Specifically, your SOP for returned dietary supplements does not include all required information. Your response dated April 8, 2024, includes a document titled Returned Product Procedure. However, the procedure does not address the requirement for quality control to conduct a material review and make a disposition decision, as required by 21 CFR 111.510. The procedure states that the food safety officer will perform these activities. Furthermore, the procedure also does not address the requirement that if the reason for a dietary supplement being returned implicates other batches, you must conduct an investigation of the manufacturing processes and each of those other batches to determine compliance with specifications, as required by 21 CFR 111.530.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nYou should take prompt action to address the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nIn addition to the above-mentioned violations, we also have the following comment:\n1. Your current finished product specification sheet for your Acetyl-glutathione product lists the test method as N\u002FA. Please update this document to include the UPLC test method that is used to test the identity, purity, and strength of the finished product.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be addressed to Rebecca Allen, Compliance Officer, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS #679737 on any submissions and within the subject line of any emails to us.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD MBA\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Western Innovations, Inc.","western-innovations-inc-679737-11132024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwestern-innovations-inc-679737-11132024","2026-10-26T08:10:31.225264+00:00","Issued","2025-01-21","679737","Food & Beverages","SJ Jernigan","2026-08-19T17:04:20.709+00:00","Via Email","2024-11-13",{"id":57,"raw":58,"subject":63,"body_html":64,"body_text":65,"firm_name":66,"letter_id":67,"created_at":45,"fei_number":20,"letter_url":68,"updated_at":69,"action_type":23,"case_status":48,"posted_date":70,"marcs_cms_no":71,"product_type":72,"closeout_date":20,"issuing_office":62,"recipient_name":73,"body_fetched_at":74,"delivery_method":75,"recipient_title":20,"reference_number":76,"action_taken_date":77,"medical_device_id":20,"response_letter_date":20},1424,[59,60,61,62,63,13,13,13],"\u003Ctime datetime=\"2024-06-13T04:00:00Z\">06\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-12T04:00:00Z\">06\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwest-coast-vape-supply-inc-685567-06122024\">West Coast Vape Supply, Inc\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2402158\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Alham Benyameen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>West Coast Vape Supply, Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>15321 Transistor Ln.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Huntington Beach\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92649\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@westcoastvapesupply.com\"> support@westcoastvapesupply.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 12, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Alham Benyameen:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwestcoastvapesupply.com and determined that electronic nicotine delivery system (ENDS) and e-liquid products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS and e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS and e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States ENDS and e-liquid products that lack a marketing authorization order: Cereal Trip Ejuice by Bad Drip 60ML, Don’t Care Bear Ejuice by Bad Drip 60ML, and Funky Republic FI3000 Disposable Vape 3000 Puffs - Apple Watermelon.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Considerations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA finds some of these products particularly concerning because the design of the Bad Drip Labs e-liquid products (see Exhibits A) are likely to appeal to youth by imitating a prescription pill bottle (see Exhibits B). Specifically, the overall presentation of the e-liquid products, including the graphical elements on their labeling and\u002For advertising, makes it appear that the products are a prescription and could reasonably result in a child or adult ingesting the products. Further, the products are likely to appeal to youth because they enable youth to conceal a tobacco product from parents, teachers, or other adults. FDA is concerned about the rising youth appeal and dramatic rise in youth use of e-liquid products. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized tobacco products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with e-liquid products.\u003C\u002Fp>\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F685567.PNG\" alt=\"Pill Bottles\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F685567-2.PNG\" alt=\"Pill Bottles\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2402158, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Atencio\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>West Coast Vape Supply, Inc.\u003Cbr>\n580 W. Cheyenne #160\u003Cbr>\nNorth Las Vegas, NV 89030\u003C\u002Fp>\n\n\u003Cp>West Coast Vape Supply, Inc.\u003Cbr>\n5445 Oceanus Dr. #102\u003Cbr>\nHuntington Beach, CA 92649\u003C\u002Fp>\n\n\u003Cp>Alham Benyameen\u003Cbr>\n16541 Gothard St., Ste. 201\u003Cbr>\nHuntington Beach CA 92657\u003C\u002Fp>\n\n\u003Cp>West Coast Vape Supply, Inc.\u003Cbr>\nc\u002Fo Registered Agents, Inc.\u003Cbr>\n401 Ryland St., Ste. 200\u003Cbr>\nReno, NV 89502\u003C\u002Fp>\n\n\u003Cp>GoDaddy, Inc.\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2402158\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nAlham Benyameen\n\nWest Coast Vape Supply, Inc\n\n15321 Transistor Ln.\n\nHuntington Beach, CA 92649\n\nUnited States\n\nsupport@westcoastvapesupply.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJune 12, 2024\n\nWARNING LETTER\n\nDear Alham Benyameen:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwestcoastvapesupply.com and determined that electronic nicotine delivery system (ENDS) and e-liquid products listed there are offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS and e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS and e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nFDA has determined that you offer for sale or distribution to customers in the United States ENDS and e-liquid products that lack a marketing authorization order: Cereal Trip Ejuice by Bad Drip 60ML, Don’t Care Bear Ejuice by Bad Drip 60ML, and Funky Republic FI3000 Disposable Vape 3000 Puffs - Apple Watermelon.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\n\nAdditional Considerations\n\nFDA finds some of these products particularly concerning because the design of the Bad Drip Labs e-liquid products (see Exhibits A) are likely to appeal to youth by imitating a prescription pill bottle (see Exhibits B). Specifically, the overall presentation of the e-liquid products, including the graphical elements on their labeling and\u002For advertising, makes it appear that the products are a prescription and could reasonably result in a child or adult ingesting the products. Further, the products are likely to appeal to youth because they enable youth to conceal a tobacco product from parents, teachers, or other adults. FDA is concerned about the rising youth appeal and dramatic rise in youth use of e-liquid products. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized tobacco products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with e-liquid products.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\n\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2402158, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Atencio\n\nActing Director\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nWest Coast Vape Supply, Inc.\n\n580 W. Cheyenne #160\n\nNorth Las Vegas, NV 89030\n\nWest Coast Vape Supply, Inc.\n\n5445 Oceanus Dr. #102\n\nHuntington Beach, CA 92649\n\nAlham Benyameen\n\n16541 Gothard St., Ste. 201\n\nHuntington Beach CA 92657\n\nWest Coast Vape Supply, Inc.\n\nc\u002Fo Registered Agents, Inc.\n\n401 Ryland St., Ste. 200\n\nReno, NV 89502\n\nGoDaddy, Inc.\n\nabuse@godaddy.com\n\nShopify, Inc.\n\nabuse@shopify.com","West Coast Vape Supply, Inc","west-coast-vape-supply-inc-685567-06122024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwest-coast-vape-supply-inc-685567-06122024","2026-10-26T08:10:31.144987+00:00","2024-06-13","685567","Tobacco","Alham Benyameen","2026-08-20T00:02:37.36+00:00","VIA UPS and Electronic Mail","RW2402158","2024-06-12",{"id":79,"raw":80,"subject":85,"body_html":86,"body_text":87,"firm_name":88,"letter_id":89,"created_at":45,"fei_number":20,"letter_url":90,"updated_at":91,"action_type":23,"case_status":48,"posted_date":92,"marcs_cms_no":93,"product_type":94,"closeout_date":20,"issuing_office":84,"recipient_name":95,"body_fetched_at":96,"delivery_method":97,"recipient_title":20,"reference_number":20,"action_taken_date":98,"medical_device_id":20,"response_letter_date":20},1466,[81,82,83,84,85,13,13,13],"\u003Ctime datetime=\"2024-05-14T13:20:00Z\">05\u002F14\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-17T04:00:00Z\">04\u002F17\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwestwood-laboratories-llc-674728-04172024\">Westwood Laboratories LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL CONFIRMED DELIVERY\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Paul A. Schirmer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Westwood Laboratories LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>710 S. Ayon Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Azusa\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91702\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 17, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Schirmer:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Westwood Laboratories LLC, FEI 2020372, at 710 S. Ayon Ave., Azusa, from October 30 to November 20, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your December 11, 2023, response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately investigate complaints received for the over-the-counter (OTC) drug products you manufacture. For example,\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A complaint for Advanced Protection SPF 30, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reporting the “entire batch is separating.” Your investigation failed to review relevant manufacturing records, including the processing parameters used to produce an emulsion of intended quality and evaluate other lots or drug products to determine the extent of the problem. Your investigation determined the product was “not properly emulsified” without adequately evaluating the processing parameters used to produce an emulsion of intended quality. You then failed to take appropriate corrective actions and the lot was reprocessed, assigned a new expiration date, refilled into the original containers, and released.\u003C\u002Fli>\n\t\u003Cli>A complaint for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reporting the product was “watery thin.” During your investigation, you obtained an out of specification (OOS) result for viscosity from a retain sample that was not adequately investigated and documented in the complaint report. Notably, your complaint report did not acknowledge the OOS and stated, “The product does not feel like it is watery thin and would apply correctly as per the retains of the lot that were pulled and evaluated.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response states you will revise the investigation and complaint procedures to include the pulling and testing of retain samples and retrain staff with the procedural improvements going forward. Your response is inadequate as you did not provide supporting documentation of these changes. Furthermore, you do not commit to evaluating your quality unit’s (QU) processes and procedures to determine whether your investigations are effectively identifying the causes of deviations and product failures to implement appropriate corrective action and preventive action (CAPA).\u003C\u002Fp>\n\n\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to manufacture safe and effective drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An independent, comprehensive review of your company’s complaint handling program that identifies deficiencies and a corresponding CAPA.\u003C\u002Fli>\n\t\u003Cli>An independent, retrospective review of all complaints, including the associated investigations of drugs within expiry as of the date of this letter. Include the drug product name, batch number, date of manufacture, production line number, a summary of the complaint, description of likely root causes, CAPA plan, and status of CAPA.\u003C\u002Fli>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture OTC drug products without adequate assurance of the quality of your raw materials. For example, you failed to test propylene glycol for diethylene glycol (DEG) and ethylene glycol (EG) used in the manufacture of your OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product. Identity testing for propylene glycol and certain other high-risk drug components\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products. You also rely on your suppliers’ certificate of analysis (COA) without adequately establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>Your response states that you will revise your specifications for components at high-risk of DEG or EG contamination to test for DEG and EG. Your response is inadequate because you did provide sufficient detail or adequate evidence of corrective actions and did not consider retrospectively testing your retained components for DEG and EG. Further, you also do not discuss how you will verify the reliability of your suppliers’ COAs nor how you will perform qualification of your suppliers.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs, including repackaged drugs at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your suppliers’ results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B., and C of the United States Pharmacopeia (USP) monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Appropriate Control over Laboratory\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to exercise appropriate controls over your high-performance liquid chromatography (HPLC) software system, such as requiring employee-specific logins, appropriate assignment of administrative privileges, and ensuring the audit trails are enabled. Furthermore, you could not locate the system’s validation documentation during the inspection.\u003C\u002Fp>\n\n\u003Cp>Your response states that the validation documentation is available on your HPLC software system, but that you require the assistance of your vendor to retrieve it. You also state that you identified an IT system administrator, trained employees enable the audit trail, and will establish a work instruction. Your response is inadequate because you failed to provide supporting evidence. You are responsible for the validation of your HPLC system despite your vendor having completed it on your behalf.\u003C\u002Fp>\n\n\u003Cp>There must be adequate document controls in place to assure product quality. CGMP compliant record keeping practices prevent data from being lost or obscured and ensure that activities are documented at the time of performance.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Verification of Microbial Testing Methods\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You revised your microbial testing methodology to utilize rapid detection media plates for aerobic and yeast and mold counts without appropriately verifying whether your revised methods are suitable for testing of your drug components and drug products. Your revised methods included shortened incubation times and failed to demonstrate your new method's ability recover organisms. Notably, the uses of the rapid detection media plates are intended for use “in the food and beverage industries.”\u003C\u002Fp>\n\n\u003Cp>Your response states that you will develop protocols and procedures for testing microbial attributes of your drug components and drugs using the rapid detection plates, and that you will validate the suitability of your alternative rapid methods following the USP. Your response is inadequate because you did not provide sufficient detail or adequate evidence of corrective actions (e.g., protocol or procedure). Your revised methods must be properly verified giving equivalent or better results when substituted for USP compendial testing.\u003C\u002Fp>\n\n\u003Cp>The ability of microbial testing methods to detect objectionable microorganisms in the presence of each drug product must be established and validated. Results generated using unverified or unvalidated methods may put consumers at risk.\u003C\u002Fp>\n\n\u003Cp>Moreover, your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance with Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\n\t\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\n\t\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to the FDA.\u003C\u002Fli>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\t\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; &nbsp; o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm uses water as a component in your OTC drug products. Your water system is not adequately qualified, controlled, maintained, and monitored to ensure that the system is operating properly and continuously producing water suitable for its intended use. For example, you did not test for objectionable microorganisms. You also failed to conduct adequate conductivity testing to ensure that your water met \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP monograph specifications. We also observed inadequate maintenance of your water system (e.g., utilization of ultraviolet lamps beyond established usage times, leaking water tank) and inadequately validated system changes (e.g., new points-of-use and the adding of \u003Cstrong>(b)(4)\u003C\u002Fstrong> were not validated).\u003C\u002Fp>\n\n\u003Cp>Your response states that you will qualify your water system according to USP &lt;1231&gt; and develop a validation master plan to address the qualification life cycle of the system and events. You state that procedures and methods will be implemented to determine whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water complies with established specifications including objectionable organisms. You provided a revised water system diagram, but no other supporting documentation. Your response is inadequate because you did not systemically review your water system to ensure that it is capable to produce water suitable for its intended use. You also did not consider retrospective testing of retained finished drug products that used water from this system.\u003C\u002Fp>\n\n\u003Cp>Water for pharmaceutical purposes must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. The lack of adequate validation provides no assurance that the system performs as intended and subsequent use of inadequately \u003Cstrong>(b)(4)\u003C\u002Fstrong> water in pharmaceutical manufacturing can adversely impact drug product quality and patient safety.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you manufacture human drugs on equipment shared with animal drugs, medical devices, and cosmetics, but failed to perform appropriate cleaning validation using your in-house cleaning and sanitizing agents. You also did not adequately evaluate difficult to clean surfaces of your shared equipment. Inadequate cleaning may result in residual product and detergents on shared equipment, risking cross contamination with various products manufactured on this equipment.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the water system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your products.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\t\u003Cli>A procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water are appropriately stringent in view of the intended use of each of the products produced by your firm. Total microbial count limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water systems are generally tighter than your current action limits for the topical dosage forms produced by your firm.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality system is inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive \u003Cstrong>(b)(4)\u003C\u002Fstrong> audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with the FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please send your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, CA 92612-2506\u003C\u002Fp>\n\n\u003Cp>Please identify your responses with the unique identifier: \u003Cstrong>CMS 674728\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>If there are any questions about the released information, please contact Yumi Hiramine, compliance officer, at Yumi.Hiramine@fda.hhs.gov or at 818-226-1839.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\n________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL CONFIRMED DELIVERY\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Paul A. Schirmer\n\nRecipient Title\n\nChief Executive Officer\n\nWestwood Laboratories LLC\n\n710 S. Ayon Avenue\n\nAzusa, CA 91702\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nApril 17, 2024\n\nDear Mr. Schirmer:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Westwood Laboratories LLC, FEI 2020372, at 710 S. Ayon Ave., Azusa, from October 30 to November 20, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your December 11, 2023, response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou failed to adequately investigate complaints received for the over-the-counter (OTC) drug products you manufacture. For example,\n\nA complaint for Advanced Protection SPF 30, Lot (b)(4), reporting the “entire batch is separating.” Your investigation failed to review relevant manufacturing records, including the processing parameters used to produce an emulsion of intended quality and evaluate other lots or drug products to determine the extent of the problem. Your investigation determined the product was “not properly emulsified” without adequately evaluating the processing parameters used to produce an emulsion of intended quality. You then failed to take appropriate corrective actions and the lot was reprocessed, assigned a new expiration date, refilled into the original containers, and released.\n\nA complaint for (b)(4), Lot (b)(4), reporting the product was “watery thin.” During your investigation, you obtained an out of specification (OOS) result for viscosity from a retain sample that was not adequately investigated and documented in the complaint report. Notably, your complaint report did not acknowledge the OOS and stated, “The product does not feel like it is watery thin and would apply correctly as per the retains of the lot that were pulled and evaluated.”\n\nYour response states you will revise the investigation and complaint procedures to include the pulling and testing of retain samples and retrain staff with the procedural improvements going forward. Your response is inadequate as you did not provide supporting documentation of these changes. Furthermore, you do not commit to evaluating your quality unit’s (QU) processes and procedures to determine whether your investigations are effectively identifying the causes of deviations and product failures to implement appropriate corrective action and preventive action (CAPA).\n\nInadequate investigations can lead to unidentified root causes, ineffective CAPA, and recurring problems that compromise the ability to manufacture safe and effective drug products.\n\nIn response to this letter, provide:\n\nAn independent, comprehensive review of your company’s complaint handling program that identifies deficiencies and a corresponding CAPA.\n\nAn independent, retrospective review of all complaints, including the associated investigations of drugs within expiry as of the date of this letter. Include the drug product name, batch number, date of manufacture, production line number, a summary of the complaint, description of likely root causes, CAPA plan, and status of CAPA.\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYou manufacture OTC drug products without adequate assurance of the quality of your raw materials. For example, you failed to test propylene glycol for diethylene glycol (DEG) and ethylene glycol (EG) used in the manufacture of your OTC (b)(4) drug product. Identity testing for propylene glycol and certain other high-risk drug components1 include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products. You also rely on your suppliers’ certificate of analysis (COA) without adequately establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\n\nYour response states that you will revise your specifications for components at high-risk of DEG or EG contamination to test for DEG and EG. Your response is inadequate because you did provide sufficient detail or adequate evidence of corrective actions and did not consider retrospectively testing your retained components for DEG and EG. Further, you also do not discuss how you will verify the reliability of your suppliers’ COAs nor how you will perform qualification of your suppliers.\n\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs, including repackaged drugs at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide:\n\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your suppliers’ results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B., and C of the United States Pharmacopeia (USP) monograph.\n\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nAppropriate Control over Laboratory\n\nYou failed to exercise appropriate controls over your high-performance liquid chromatography (HPLC) software system, such as requiring employee-specific logins, appropriate assignment of administrative privileges, and ensuring the audit trails are enabled. Furthermore, you could not locate the system’s validation documentation during the inspection.\n\nYour response states that the validation documentation is available on your HPLC software system, but that you require the assistance of your vendor to retrieve it. You also state that you identified an IT system administrator, trained employees enable the audit trail, and will establish a work instruction. Your response is inadequate because you failed to provide supporting evidence. You are responsible for the validation of your HPLC system despite your vendor having completed it on your behalf.\n\nThere must be adequate document controls in place to assure product quality. CGMP compliant record keeping practices prevent data from being lost or obscured and ensure that activities are documented at the time of performance.\n\nVerification of Microbial Testing Methods\n\nYou revised your microbial testing methodology to utilize rapid detection media plates for aerobic and yeast and mold counts without appropriately verifying whether your revised methods are suitable for testing of your drug components and drug products. Your revised methods included shortened incubation times and failed to demonstrate your new method's ability recover organisms. Notably, the uses of the rapid detection media plates are intended for use “in the food and beverage industries.”\n\nYour response states that you will develop protocols and procedures for testing microbial attributes of your drug components and drugs using the rapid detection plates, and that you will validate the suitability of your alternative rapid methods following the USP. Your response is inadequate because you did not provide sufficient detail or adequate evidence of corrective actions (e.g., protocol or procedure). Your revised methods must be properly verified giving equivalent or better results when substituted for USP compendial testing.\n\nThe ability of microbial testing methods to detect objectionable microorganisms in the presence of each drug product must be established and validated. Results generated using unverified or unvalidated methods may put consumers at risk.\n\nMoreover, your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance with Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\nA management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to the FDA.\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\n\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n4. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYour firm uses water as a component in your OTC drug products. Your water system is not adequately qualified, controlled, maintained, and monitored to ensure that the system is operating properly and continuously producing water suitable for its intended use. For example, you did not test for objectionable microorganisms. You also failed to conduct adequate conductivity testing to ensure that your water met (b)(4) USP monograph specifications. We also observed inadequate maintenance of your water system (e.g., utilization of ultraviolet lamps beyond established usage times, leaking water tank) and inadequately validated system changes (e.g., new points-of-use and the adding of (b)(4) were not validated).\n\nYour response states that you will qualify your water system according to USP \u003C1231> and develop a validation master plan to address the qualification life cycle of the system and events. You state that procedures and methods will be implemented to determine whether the (b)(4) water complies with established specifications including objectionable organisms. You provided a revised water system diagram, but no other supporting documentation. Your response is inadequate because you did not systemically review your water system to ensure that it is capable to produce water suitable for its intended use. You also did not consider retrospective testing of retained finished drug products that used water from this system.\n\nWater for pharmaceutical purposes must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. The lack of adequate validation provides no assurance that the system performs as intended and subsequent use of inadequately (b)(4) water in pharmaceutical manufacturing can adversely impact drug product quality and patient safety.\n\nFurthermore, you manufacture human drugs on equipment shared with animal drugs, medical devices, and cosmetics, but failed to perform appropriate cleaning validation using your in-house cleaning and sanitizing agents. You also did not adequately evaluate difficult to clean surfaces of your shared equipment. Inadequate cleaning may result in residual product and detergents on shared equipment, risking cross contamination with various products manufactured on this equipment.\n\nIn response to this letter, provide:\n\nA comprehensive remediation plan for the design, control, and maintenance of the water system.\n\no A (b)(4) water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\n\nYour total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your products.\n\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n\nA procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\n\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) Water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm. Total microbial count limits for (b)(4) Water systems are generally tighter than your current action limits for the topical dosage forms produced by your firm.\n\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\nQuality Systems\n\nYour firm’s quality system is inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive (b)(4) audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with the FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease send your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food and Drug Administration\n\n19701 Fairchild Road\n\nIrvine, CA 92612-2506\n\nPlease identify your responses with the unique identifier: CMS 674728.\n\nIf there are any questions about the released information, please contact Yumi Hiramine, compliance officer, at Yumi.Hiramine@fda.hhs.gov or at 818-226-1839.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\n________________________\n\n1 Components with higher risk of DEG or EG contamination compared to other drug components.","Westwood Laboratories LLC","westwood-laboratories-llc-674728-04172024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwestwood-laboratories-llc-674728-04172024","2026-10-26T08:10:31.393697+00:00","2024-05-14","674728","Drugs","Mr. Paul A. Schirmer","2026-08-20T00:06:24.598+00:00","VIA EMAIL CONFIRMED DELIVERY","2024-04-17",{"id":100,"raw":101,"subject":106,"body_html":107,"body_text":108,"firm_name":109,"letter_id":110,"created_at":111,"fei_number":20,"letter_url":112,"updated_at":113,"action_type":23,"case_status":48,"posted_date":114,"marcs_cms_no":115,"product_type":51,"closeout_date":20,"issuing_office":105,"recipient_name":116,"body_fetched_at":117,"delivery_method":118,"recipient_title":20,"reference_number":20,"action_taken_date":119,"medical_device_id":20,"response_letter_date":20},2949,[102,103,104,105,106,13,13,13],"\u003Ctime datetime=\"2021-12-28T14:20:00Z\">12\u002F28\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-07T05:00:00Z\">12\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwestern-herb-products-inc-615439-12072021\">Western Herb Products, Inc.\u003C\u002Fa>","Office of Human and Animal Food Operations – West Division 6","CGMP\u002FDietary Supplement\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Certified Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Rhonda H. Summerland\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Western Herb Products, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>P.O. Box 115\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Index\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98256\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations – West Division 6\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 7, 2021\u003C\u002Fp>\n\n\u003Cp>In reply, refer to CMS 615439\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Summerland:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your dietary supplement manufacturing facility located at 21624 Sertz Road, Index, Washington, on May 3, 4, and 12, 2021. During the inspection, we identified serious violations of Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111), Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. These violations cause the dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 United States Code (U.S.C.) § 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. In addition, the Wormwood\u002FAloes dietary supplement product that you manufacture is misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343]. You can find the Act and FDA regulations through links in FDA's home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>We received an e-mail correspondence from you dated May 31, 2021, written in response to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection. We address your response below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Dietary Supplement CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your significant violations of CGMP requirements are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish the required specifications for points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record (MMR), as required by 21 CFR 111.70(a). You do not have written specifications to ensure the consistent production of your finished dietary supplements. Specifically, for your Wormwood\u002FAloes dietary supplement capsules, lot #06821-6:\u003C\u002Fp>\n\n\u003Cp>a. For your components:\u003Cbr>\n&nbsp; i. You failed to establish an identity specification, as required in 21 CFR 111.70(b)(1).\u003Cbr>\n&nbsp; ii. You failed to establish component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplement manufactured using the components are met, as required in 21 CFR 111.70(b)(2).\u003Cbr>\n&nbsp; iii. You failed to establish limits on those types of contamination that may adulterate or may lead to adulteration of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required in 21 CFR 111.70(b)(3).\u003Cbr>\nb. You failed to establish in-process specifications for any point, step, or stage in the MMR where control is necessary to help ensure that specifications are met for the identity, purity, strength, and composition of the dietary supplement, as required by 21 CFR 111.70(c)(1). Included in the manufacture of the Wormwood\u002FAloes dietary supplement is the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the wormwood powder and aloe powder. A \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>inspection is performed on the herb(s) after \u003Cstrong>(b)(4)\u003C\u002Fstrong> the blend of wormwood powder and aloe powder; however, an acceptance criterion related to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> blend (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) does not ensure that specifications are met for the composition of the dietary supplement.\u003Cbr>\nc. You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e).\u003C\u002Fp>\n\n\u003Cp>We received and reviewed your revised specification sheets for the dietary ingredients, wormwood and aloe, and for the Wormwood\u002FAloes dietary supplement submitted with your May 31, 2021, written response to the inspection and have the following comments:\u003C\u002Fp>\n\n\u003Cp>The specifications were revised to include identification by microscopic examination with an acceptance criterion of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and the purity strength specification states “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” The identity specification is inadequate in that the microscopic specification fails to include characteristics that will allow you to confirm the identity of the ingredient at issue, such as specific microscopic characteristics that should be observed for comparison to the standard. We are also unable to evaluate the sufficiency of your “Purity\u002FStrength” standard on your revised specification sheet, which states, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” as this specification does not provide the specific portion or percentage that is wormwood or aloe powder, nor does it provide the specific concentration that is expected for each of the powders. The documentation you provided fails to provide a specification for composition for the individual wormwood powder and aloe powder.\u003C\u002Fp>\n\n\u003Cp>Further, you included microscopic examination in your revised specification sheets in addition to organoleptic and macroscopic methods to identify the botanical powder and provided photos of two products showing a comparison of their physical structures under the microscope at different forms (whole leaf, rough cut, and finer cut). Microscopic analyses may be an appropriate identity test for whole or coarsely cut botanical parts, but it may not be an appropriate identity test for powdered or extracted botanicals because of decreased reliability, or in those instances where misidentification of botanicals is known to occur [Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, 72 Fed. Reg. 34752, 34852 (June 25, 2007)]. The physical characteristic of a plant significantly decreases as the plant is cut into a finer size or powder, as evidenced in the photos you provided.\u003C\u002Fp>\n\n\u003Cp>Your component and finished product specifications regarding limits of contamination are inadequate because you did not specify which heavy metals are subject to the specification (component) or are not established (finished product).\u003C\u002Fp>\n\n\u003Cp>Your finished product specification is further inadequate in that identity cannot be determined by verification of input as it does not provide a specific physical or qualitative property that can be used to confirm identity, nor does it include a numeric or quantitative limit for comparison; purity as a function of no additives or flow agents does not provide the specific portion or percentage that is wormwood and aloe powders; strength as an amount of dietary ingredient cannot be adequately evaluated because the method by which the strength can be verified was not provided; and composition as a statement of a blend of OG Wormwood (Artemisia absinthium) leaf and cape aloes (Aloes ferox) leaf powders in “00” gelatin capsules does not provide the percent of wormwood and aloe powders comprised in the blend.\u003C\u002Fp>\n\n\u003Cp>Further, you have not established specifications for the empty hard-shell gelatin capsule #00 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) used in the manufacture of your dietary supplement capsules.\u003C\u002Fp>\n\n\u003Cp>Finally, you provided a label proof that includes specifications (e.g., die number, dimensions stock, and unwind directions). To the extent that you intend to use the label proof to satisfy the requirement for label specifications under 21 CFR 111.70(d), we note that it is unclear if this is the label used in all labeling operations or if the specifications provided are the official labels. Furthermore, the label proof does not have approval by your quality unit documented on the record.\u003C\u002Fp>\n\n\u003Cp>Moreover, your response dated May 31, 2021, did not include any interim corrective action to ensure that the dietary supplements that you manufacture and distribute are what they purport to be and are free from contamination. Although you stated during the inspection that it would take approximately six months to complete the majority of your product specifications, and longer than six months for those products that you order only once or twice a year, you did not provide additional information about this timeline in your response or explain why it would take six months, nor did you specify corrections that you would make in the meantime.\u003C\u002Fp>\n\n\u003Cp>Once you have established the specifications identified above, you must verify that the specifications are met in accordance with 21 CFR 111.73 and 21 CFR 111.75, and you must make and keep records of the specifications established in accordance with 21 CFR 111.95(b)(1). Your Quality Control Personnel must approve specifications, among other things, as required by 21 CFR 111.105(a).\u003C\u002Fp>\n\n\u003Cp>2. You failed to prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, which includes all required information, as required by 21 CFR 111.205(a) and 21 CFR 111.210. Specifically, during the inspection, when the FDA investigator requested information about your MMRs, you provided a document titled “Master Manufacturing Record,” dated March 8, 2021, for the manufacture of the Wormwood\u002FAloes dietary supplement. The document lacked the following information that must be included in an MMR, as required in 21 CFR 111.210:\u003C\u002Fp>\n\n\u003Cp>a. The strength and concentration of each dietary ingredient for each batch size [21 CFR 111.210(a)];\u003Cbr>\nb. A complete list of components to be used [21 CFR 111.210(b)];\u003Cbr>\nc. An accurate statement of the weight or measure of each component to be used [21 CFR 111.210(c)];\u003Cbr>\nd. The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label and the identity of each ingredient that will declared on the ingredients list of the dietary supplement [21 CFR 111.210(d)];\u003Cbr>\ne. A statement of any intentional overage amount of a dietary ingredient [21 CFR 111.210(e)];\u003Cbr>\nf. A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made [21 CFR 111.210(f)];\u003Cbr>\ng. A description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label [21 CFR 111.210(g)]; and\u003Cbr>\nh. The following written instructions:\u003Cbr>\n&nbsp; i. Specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled, as specified in the MMR [21 CFR 111.210(h)(1)];\u003Cbr>\n&nbsp; ii. Procedures for sampling and a cross reference to procedures for tests or examinations [21 CFR 111.210(h)(2)];\u003Cbr>\n&nbsp; iii. Specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record [21 CFR 111.210(h)(3)]; and\u003Cbr>\n&nbsp; iv. Corrective action plans for use when a specification is not met [21 CFR 111.210(h)(5)].\u003C\u002Fp>\n\n\u003Cp>We received your revised MMRs submitted with your May 31, 2021, written response to the inspection. Our review of these documents indicates they are inadequate because they continue to lack the required information for an MMR as listed above.\u003C\u002Fp>\n\n\u003Cp>3. You failed to prepare a batch production record (BPR) every time you manufactured a batch of dietary supplement, which includes all required information, as required by 21 CFR 111.255(a) and 21 CFR 111.260. Specifically, the BPR you provided for your Wormwood\u002FAloes dietary supplement lacked the following information that must be included in a BPR, as required by 21 CFR 111.260:\u003C\u002Fp>\n\n\u003Cp>a. The identity of equipment used in producing the batch [21 CFR 111.260(b)];\u003Cbr>\nb. The date and time of the maintenance, cleaning, and sanitizing of the equipment used in producing the batch, or a cross-reference to records, such as individual equipment logs where the information is retained [21 CFR 111.260(c)];\u003Cbr>\nc. The identity and weight or measure of each component used [21 CFR 111.260(e)];\u003Cbr>\nd. A statement of the actual yield and a statement of the percentage of theoretical yield at the appropriate phases of processing [21 CFR 111.260(f)];\u003Cbr>\ne. The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\u003Cbr>\nf. Documentation that the finished dietary supplement meets specifications for identity, purity, strength, composition, and limits on contamination and for packaging and labeling [21 CFR 111.260(i)];\u003Cbr>\ng. Documentation, at the time of performance, of the manufacture of the batch, including the date on which each step of the master manufacturing record was performed and the initials of the persons performing each step [21 CFR 111.260(j)(1)];\u003Cbr>\nh. Documentation, at the time of performance, of the manufacture of the batch, including the initials of the person responsible for weighing or measuring each component used in the batch, the person responsible for verifying the weight or measure, the person responsible for adding the component to the batch, and the person responsible for verifying the addition of components [21 CFR 111.260(j)(2)];\u003Cbr>\ni. Documentation, at the time of performance, of packaging and labeling operations, including the unique identifier you assigned to packaging and labels used, an actual or representative label of the finished product as specified in the master manufacturing record, and the results of any tests or examinations conducted on packaged and labeled dietary supplements [21 CFR 111.260(k)]; and\u003Cbr>\nj. Documentation, at the time of performance, that the quality control personnel reviewed the batch production record, approved, or rejected any reprocessing or repackaging, approved, and released the batch or rejected the batch for distribution, and approved and released or rejected the packaged and labeled dietary supplement [21 CFR 111.260(l)].\u003C\u002Fp>\n\n\u003Cp>We are unable to adequately assess your corrective action submitted in your May 31, 2021, response for this observation because you did not provide documentation for review that demonstrates you are preparing a BPR that includes all required information for every manufactured batch of dietary supplement.\u003C\u002Fp>\n\n\u003Cp>4. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any processing, as required by 21 CFR 111.103. Specifically, you have no written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any processing.\u003C\u002Fp>\n\n\u003Cp>Once you have established your quality control written procedures, you must implement quality control operations in your manufacturing, packaging, labeling, and holding operations, as required by 21 CFR 111.65.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your revised Standard Operating Procedures (SOPs) submitted with your May 31, 2021, written response. Section IV Quality Control\u002FQA of your SOP includes the duties of quality control, duties of quality assurance, and inspection of materials. However, it does not include written procedures documenting how you conduct a material review, make a disposition decision, and approve or reject any reprocessing related to ingredients, in-process material, finished products, and packaging and labeling components.\u003C\u002Fp>\n\n\u003Cp>5. You failed to establish and follow written procedures to fulfill the requirements for product complaints, as required by 21 CFR 111.553. Specifically, you have no written procedures for product complaints.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your revised SOPs submitted with your May 31, 2021, written response. Section I Materials of your SOP includes a subsection on product returns which describes your complaint procedure. It states that complaints are addressed on an individual basis, and if a concern about a specific lot of herbs is warranted, customers who received the lot are notified as noted in your recall plan. Your written procedure is inadequate in that it does not provide sufficient information to determine whether a qualified person will review and investigate product complaints to determine whether the product complaint involves a possible failure of a dietary supplement to meet any of its specifications, including those specifications and other requirements that, if not met, may result in a risk of illness or injury; whether quality control personnel will review and approve decisions about whether to investigate a product complaint and review and approve the findings and follow-up action of any investigation performed; and whether the required review and investigation of the product complaint by a qualified person, and the review by quality control personnel about whether to investigate a product complaint, and the findings and follow-up action of any investigation performed, must extend to all relevant batches and records, as required by 21 CFR 111.553 and 21 CFR 111.560.\u003C\u002Fp>\n\n\u003Cp>Note that after you have established such procedures, you must make and keep a written record of every product complaint, as required by 21 CFR 111.570(b)(2).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>6. Your Wormwood\u002FAloes dietary supplement is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] in that the labels fails to identify the appropriate part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1). For example:\u003C\u002Fp>\n\n\u003Cp>a. The label indicated that \u003Cem>Artemisia absinthium\u003C\u002Fem> is derived from the leaf part of the plant, however, the specification sheet indicated that the botanical ingredient is derived from the aerial parts, which include the entire plant parts that grow above the ground.\u003Cbr>\nb. The label indicated that \u003Cem>Aloe ferox\u003C\u002Fem> is derived from the leaf part of the plant, however, the supplier specification sheet indicated it is derived from the juice or resin from leaves.\u003C\u002Fp>\n\n\u003Cp>The plant part declared on the product label must be consistent with the actual plant part identity as indicated on the specification sheet.\u003C\u002Fp>\n\n\u003Cp>7. Your Wormwood\u002FAloes product is misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of the nutrition information on the labeling of your product does not comply with 21 CFR 101.36. For example:\u003C\u002Fp>\n\n\u003Cp>a. The title, \"Supplement Facts,\" is not larger than all other print in the panel [21 CFR 101.36(e)(1)];\u003Cbr>\nb. The title and all headings are not bolded to distinguish them from the other information [21 CFR 101.36(e)(1)];\u003Cbr>\nc. The Serving Size is not placed under the \"Supplement Facts\" heading and not aligned on the left side of the nutrition label [21 CFR 101.36(b)(1)]; and\u003Cbr>\nd. There are no spaces between text lines and the letters within the panel touch one another and, in general, the label is not offset from the remainder of the label in a box and does not have the bolding, heavy bars, etc. [21 CFR 101.36(e)].\u003C\u002Fp>\n\n\u003Cp>8. Your Wormwood\u002FAloes product is misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product label fails to declare the common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically, \u003Cem>Artemisia absinthium\u003C\u002Fem> and \u003Cem>Aloe ferox\u003C\u002Fem> are not the standardized common names for these dietary ingredients. Furthermore, the product specification sheet and master manufacturing records indicate the product’s dietary ingredients are powdered extracts, but the product label fails to state the dietary ingredients are extracts.\u003C\u002Fp>\n\n\u003Cp>9. Your Wormwood\u002FAloes product is misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because the label fails to declare the net quantity of contents on the principal display panel, as required by 21 CFR 101.7. Specifically, your label states that “This package contains approximately” 300 “00” capsules. “Approximately” is not provided for in 21 CFR 101.7.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at 425-302-0413.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Miriam R. Burbach\u003Cbr>\nDistrict Director\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food\u003Cbr>\nOperations – West Division 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nCertified Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nRhonda H. Summerland\n\nRecipient Title\n\nPresident\n\nWestern Herb Products, Inc.\n\nP.O. Box 115\n\nIndex, WA 98256\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations – West Division 6\n\nUnited States\n\nDecember 7, 2021\n\nIn reply, refer to CMS 615439\n\nWARNING LETTER\n\nDear Dr. Summerland:\n\nThe United States Food and Drug Administration (FDA) inspected your dietary supplement manufacturing facility located at 21624 Sertz Road, Index, Washington, on May 3, 4, and 12, 2021. During the inspection, we identified serious violations of Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111), Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. These violations cause the dietary supplement products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 United States Code (U.S.C.) § 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. In addition, the Wormwood\u002FAloes dietary supplement product that you manufacture is misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343]. You can find the Act and FDA regulations through links in FDA's home page at www.fda.gov.\n\nWe received an e-mail correspondence from you dated May 31, 2021, written in response to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection. We address your response below, in relation to each of the noted violations.\n\nDietary Supplement CGMP Violations\n\nYour significant violations of CGMP requirements are as follows:\n\n1. You failed to establish the required specifications for points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record (MMR), as required by 21 CFR 111.70(a). You do not have written specifications to ensure the consistent production of your finished dietary supplements. Specifically, for your Wormwood\u002FAloes dietary supplement capsules, lot #06821-6:\n\na. For your components:\n\ni. You failed to establish an identity specification, as required in 21 CFR 111.70(b)(1).\n\nii. You failed to establish component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplement manufactured using the components are met, as required in 21 CFR 111.70(b)(2).\n\niii. You failed to establish limits on those types of contamination that may adulterate or may lead to adulteration of the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required in 21 CFR 111.70(b)(3).\n\nb. You failed to establish in-process specifications for any point, step, or stage in the MMR where control is necessary to help ensure that specifications are met for the identity, purity, strength, and composition of the dietary supplement, as required by 21 CFR 111.70(c)(1). Included in the manufacture of the Wormwood\u002FAloes dietary supplement is the (b)(4) and (b)(4) of the wormwood powder and aloe powder. A (b)(4) inspection is performed on the herb(s) after (b)(4) the blend of wormwood powder and aloe powder; however, an acceptance criterion related to the (b)(4) of the (b)(4) blend (e.g., (b)(4)) does not ensure that specifications are met for the composition of the dietary supplement.\n\nc. You failed to establish product specifications for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contaminants that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e).\n\nWe received and reviewed your revised specification sheets for the dietary ingredients, wormwood and aloe, and for the Wormwood\u002FAloes dietary supplement submitted with your May 31, 2021, written response to the inspection and have the following comments:\n\nThe specifications were revised to include identification by microscopic examination with an acceptance criterion of “(b)(4),” and the purity strength specification states “(b)(4).” The identity specification is inadequate in that the microscopic specification fails to include characteristics that will allow you to confirm the identity of the ingredient at issue, such as specific microscopic characteristics that should be observed for comparison to the standard. We are also unable to evaluate the sufficiency of your “Purity\u002FStrength” standard on your revised specification sheet, which states, “(b)(4),” as this specification does not provide the specific portion or percentage that is wormwood or aloe powder, nor does it provide the specific concentration that is expected for each of the powders. The documentation you provided fails to provide a specification for composition for the individual wormwood powder and aloe powder.\n\nFurther, you included microscopic examination in your revised specification sheets in addition to organoleptic and macroscopic methods to identify the botanical powder and provided photos of two products showing a comparison of their physical structures under the microscope at different forms (whole leaf, rough cut, and finer cut). Microscopic analyses may be an appropriate identity test for whole or coarsely cut botanical parts, but it may not be an appropriate identity test for powdered or extracted botanicals because of decreased reliability, or in those instances where misidentification of botanicals is known to occur [Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, 72 Fed. Reg. 34752, 34852 (June 25, 2007)]. The physical characteristic of a plant significantly decreases as the plant is cut into a finer size or powder, as evidenced in the photos you provided.\n\nYour component and finished product specifications regarding limits of contamination are inadequate because you did not specify which heavy metals are subject to the specification (component) or are not established (finished product).\n\nYour finished product specification is further inadequate in that identity cannot be determined by verification of input as it does not provide a specific physical or qualitative property that can be used to confirm identity, nor does it include a numeric or quantitative limit for comparison; purity as a function of no additives or flow agents does not provide the specific portion or percentage that is wormwood and aloe powders; strength as an amount of dietary ingredient cannot be adequately evaluated because the method by which the strength can be verified was not provided; and composition as a statement of a blend of OG Wormwood (Artemisia absinthium) leaf and cape aloes (Aloes ferox) leaf powders in “00” gelatin capsules does not provide the percent of wormwood and aloe powders comprised in the blend.\n\nFurther, you have not established specifications for the empty hard-shell gelatin capsule #00 ((b)(4)) used in the manufacture of your dietary supplement capsules.\n\nFinally, you provided a label proof that includes specifications (e.g., die number, dimensions stock, and unwind directions). To the extent that you intend to use the label proof to satisfy the requirement for label specifications under 21 CFR 111.70(d), we note that it is unclear if this is the label used in all labeling operations or if the specifications provided are the official labels. Furthermore, the label proof does not have approval by your quality unit documented on the record.\n\nMoreover, your response dated May 31, 2021, did not include any interim corrective action to ensure that the dietary supplements that you manufacture and distribute are what they purport to be and are free from contamination. Although you stated during the inspection that it would take approximately six months to complete the majority of your product specifications, and longer than six months for those products that you order only once or twice a year, you did not provide additional information about this timeline in your response or explain why it would take six months, nor did you specify corrections that you would make in the meantime.\n\nOnce you have established the specifications identified above, you must verify that the specifications are met in accordance with 21 CFR 111.73 and 21 CFR 111.75, and you must make and keep records of the specifications established in accordance with 21 CFR 111.95(b)(1). Your Quality Control Personnel must approve specifications, among other things, as required by 21 CFR 111.105(a).\n\n2. You failed to prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, which includes all required information, as required by 21 CFR 111.205(a) and 21 CFR 111.210. Specifically, during the inspection, when the FDA investigator requested information about your MMRs, you provided a document titled “Master Manufacturing Record,” dated March 8, 2021, for the manufacture of the Wormwood\u002FAloes dietary supplement. The document lacked the following information that must be included in an MMR, as required in 21 CFR 111.210:\n\na. The strength and concentration of each dietary ingredient for each batch size [21 CFR 111.210(a)];\n\nb. A complete list of components to be used [21 CFR 111.210(b)];\n\nc. An accurate statement of the weight or measure of each component to be used [21 CFR 111.210(c)];\n\nd. The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label and the identity of each ingredient that will declared on the ingredients list of the dietary supplement [21 CFR 111.210(d)];\n\ne. A statement of any intentional overage amount of a dietary ingredient [21 CFR 111.210(e)];\n\nf. A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made [21 CFR 111.210(f)];\n\ng. A description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label [21 CFR 111.210(g)]; and\n\nh. The following written instructions:\n\ni. Specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled, as specified in the MMR [21 CFR 111.210(h)(1)];\n\nii. Procedures for sampling and a cross reference to procedures for tests or examinations [21 CFR 111.210(h)(2)];\n\niii. Specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record [21 CFR 111.210(h)(3)]; and\n\niv. Corrective action plans for use when a specification is not met [21 CFR 111.210(h)(5)].\n\nWe received your revised MMRs submitted with your May 31, 2021, written response to the inspection. Our review of these documents indicates they are inadequate because they continue to lack the required information for an MMR as listed above.\n\n3. You failed to prepare a batch production record (BPR) every time you manufactured a batch of dietary supplement, which includes all required information, as required by 21 CFR 111.255(a) and 21 CFR 111.260. Specifically, the BPR you provided for your Wormwood\u002FAloes dietary supplement lacked the following information that must be included in a BPR, as required by 21 CFR 111.260:\n\na. The identity of equipment used in producing the batch [21 CFR 111.260(b)];\n\nb. The date and time of the maintenance, cleaning, and sanitizing of the equipment used in producing the batch, or a cross-reference to records, such as individual equipment logs where the information is retained [21 CFR 111.260(c)];\n\nc. The identity and weight or measure of each component used [21 CFR 111.260(e)];\n\nd. A statement of the actual yield and a statement of the percentage of theoretical yield at the appropriate phases of processing [21 CFR 111.260(f)];\n\ne. The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\n\nf. Documentation that the finished dietary supplement meets specifications for identity, purity, strength, composition, and limits on contamination and for packaging and labeling [21 CFR 111.260(i)];\n\ng. Documentation, at the time of performance, of the manufacture of the batch, including the date on which each step of the master manufacturing record was performed and the initials of the persons performing each step [21 CFR 111.260(j)(1)];\n\nh. Documentation, at the time of performance, of the manufacture of the batch, including the initials of the person responsible for weighing or measuring each component used in the batch, the person responsible for verifying the weight or measure, the person responsible for adding the component to the batch, and the person responsible for verifying the addition of components [21 CFR 111.260(j)(2)];\n\ni. Documentation, at the time of performance, of packaging and labeling operations, including the unique identifier you assigned to packaging and labels used, an actual or representative label of the finished product as specified in the master manufacturing record, and the results of any tests or examinations conducted on packaged and labeled dietary supplements [21 CFR 111.260(k)]; and\n\nj. Documentation, at the time of performance, that the quality control personnel reviewed the batch production record, approved, or rejected any reprocessing or repackaging, approved, and released the batch or rejected the batch for distribution, and approved and released or rejected the packaged and labeled dietary supplement [21 CFR 111.260(l)].\n\nWe are unable to adequately assess your corrective action submitted in your May 31, 2021, response for this observation because you did not provide documentation for review that demonstrates you are preparing a BPR that includes all required information for every manufactured batch of dietary supplement.\n\n4. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any processing, as required by 21 CFR 111.103. Specifically, you have no written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any processing.\n\nOnce you have established your quality control written procedures, you must implement quality control operations in your manufacturing, packaging, labeling, and holding operations, as required by 21 CFR 111.65.\n\nWe have reviewed your revised Standard Operating Procedures (SOPs) submitted with your May 31, 2021, written response. Section IV Quality Control\u002FQA of your SOP includes the duties of quality control, duties of quality assurance, and inspection of materials. However, it does not include written procedures documenting how you conduct a material review, make a disposition decision, and approve or reject any reprocessing related to ingredients, in-process material, finished products, and packaging and labeling components.\n\n5. You failed to establish and follow written procedures to fulfill the requirements for product complaints, as required by 21 CFR 111.553. Specifically, you have no written procedures for product complaints.\n\nWe have reviewed your revised SOPs submitted with your May 31, 2021, written response. Section I Materials of your SOP includes a subsection on product returns which describes your complaint procedure. It states that complaints are addressed on an individual basis, and if a concern about a specific lot of herbs is warranted, customers who received the lot are notified as noted in your recall plan. Your written procedure is inadequate in that it does not provide sufficient information to determine whether a qualified person will review and investigate product complaints to determine whether the product complaint involves a possible failure of a dietary supplement to meet any of its specifications, including those specifications and other requirements that, if not met, may result in a risk of illness or injury; whether quality control personnel will review and approve decisions about whether to investigate a product complaint and review and approve the findings and follow-up action of any investigation performed; and whether the required review and investigation of the product complaint by a qualified person, and the review by quality control personnel about whether to investigate a product complaint, and the findings and follow-up action of any investigation performed, must extend to all relevant batches and records, as required by 21 CFR 111.553 and 21 CFR 111.560.\n\nNote that after you have established such procedures, you must make and keep a written record of every product complaint, as required by 21 CFR 111.570(b)(2).\n\nMisbranded Dietary Supplements\n\n6. Your Wormwood\u002FAloes dietary supplement is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] in that the labels fails to identify the appropriate part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1). For example:\n\na. The label indicated that Artemisia absinthium is derived from the leaf part of the plant, however, the specification sheet indicated that the botanical ingredient is derived from the aerial parts, which include the entire plant parts that grow above the ground.\n\nb. The label indicated that Aloe ferox is derived from the leaf part of the plant, however, the supplier specification sheet indicated it is derived from the juice or resin from leaves.\n\nThe plant part declared on the product label must be consistent with the actual plant part identity as indicated on the specification sheet.\n\n7. Your Wormwood\u002FAloes product is misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of the nutrition information on the labeling of your product does not comply with 21 CFR 101.36. For example:\n\na. The title, \"Supplement Facts,\" is not larger than all other print in the panel [21 CFR 101.36(e)(1)];\n\nb. The title and all headings are not bolded to distinguish them from the other information [21 CFR 101.36(e)(1)];\n\nc. The Serving Size is not placed under the \"Supplement Facts\" heading and not aligned on the left side of the nutrition label [21 CFR 101.36(b)(1)]; and\n\nd. There are no spaces between text lines and the letters within the panel touch one another and, in general, the label is not offset from the remainder of the label in a box and does not have the bolding, heavy bars, etc. [21 CFR 101.36(e)].\n\n8. Your Wormwood\u002FAloes product is misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product label fails to declare the common or usual names of each ingredient used, as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically, Artemisia absinthium and Aloe ferox are not the standardized common names for these dietary ingredients. Furthermore, the product specification sheet and master manufacturing records indicate the product’s dietary ingredients are powdered extracts, but the product label fails to state the dietary ingredients are extracts.\n\n9. Your Wormwood\u002FAloes product is misbranded within the meaning of section 403(e)(2) of the Act [21 U.S.C. § 343(e)(2)] because the label fails to declare the net quantity of contents on the principal display panel, as required by 21 CFR 101.7. Specifically, your label states that “This package contains approximately” 300 “00” capsules. “Approximately” is not provided for in 21 CFR 101.7.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at 425-302-0413.\n\nSincerely,\n\n\u002FS\u002F\n\nMiriam R. Burbach\n\nDistrict Director\n\nProgram Division Director\n\nOffice of Human and Animal Food\n\nOperations – West Division 6","Western Herb Products, Inc.","western-herb-products-inc-615439-12072021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwestern-herb-products-inc-615439-12072021","2026-10-26T08:10:31.194847+00:00","2021-12-28","615439","Rhonda H. Summerland","2026-08-20T02:18:14.398+00:00","Certified Mail","2021-12-07",{"id":121,"raw":122,"subject":106,"body_html":126,"body_text":127,"firm_name":128,"letter_id":129,"created_at":45,"fei_number":20,"letter_url":130,"updated_at":131,"action_type":23,"case_status":48,"posted_date":132,"marcs_cms_no":133,"product_type":134,"closeout_date":20,"issuing_office":125,"recipient_name":135,"body_fetched_at":136,"delivery_method":137,"recipient_title":20,"reference_number":20,"action_taken_date":77,"medical_device_id":20,"response_letter_date":20},1357,[123,60,124,125,106,13,13,13],"\u003Ctime datetime=\"2024-07-23T13:20:00Z\">07\u002F23\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwest-coast-laboratories-inc-672954-06122024\">West Coast Laboratories, Inc.\u003C\u002Fa>","Division of Human and Animal Food Operations West V","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert P. Bailly\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Acting CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>West Coast Laboratories, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>116 E. Alondra Blvd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gardena\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90248-2806\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 12, 2024\u003C\u002Fp>\n\n\u003Cp>WL 672954\u003Cbr>\n\u003Cbr>\nDear Mr. Bailly:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your facility located at 116 E. Alondra Blvd., Gardena, CA from October 3 through October 24, 2023. Based on the inspectional findings we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection on October 24, 2023, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your written responses dated November 15, December 1, and December 7, 2023. Your November 15 and December 1, 2023, communications did not address the specific observations. We address your December 7, 2023, response below, where relevant.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility from October 3, 2023, through October 24, 2023, identified serious violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the Calcium Pyruvate, Chromium Picolinate, and CalComplex products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not conduct at least one appropriate test or examination to verify the identity of a dietary ingredient, prior to its use, as required by 21 CFR 111.75(a)(1)(i), nor did you petition the agency under 21 CFR 111.75(a)(1)(ii) for exemption from such testing.\u003Cbr>\n\u003Cbr>\nSpecifically, you did not conduct identity testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Naticol HPMG Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and Aquamin F \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of CalComplex Lot 523008; you did not conduct identity testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of Chromium Picolinate Lot 40223; nor did you conduct identity testing for Calcium Pyruvate Lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> or Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of Calcium Pyruvate Lot 150822. You also have not petitioned the agency for an exemption for such testing.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated December 7 ,2023, in which you provided revised raw material specifications for Aquamin F, Calcium Pyruvate, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and Naticol HPMG. Each of these documents purports to establish a specification of more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> match by FTIR. However, you did not provide test records to support that you are conducting identity testing in accordance with the established identity specifications for each of these components.\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically:\u003C\u002Fp>\n\n\u003Cp>a. For \u003Cstrong>(b)(4)\u003C\u002Fstrong> you do not have specifications to ensure the purity, strength, and composition of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of CalComplex.\u003C\u002Fp>\n\n\u003Cp>b. For Naticol HPMG you do not have specifications to ensure the purity, strength, and composition of proteins used in the manufacture of CalComplex.\u003C\u002Fp>\n\n\u003Cp>c. For Aquamin F you do not have specifications to ensure the purity, strength, and composition of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of CalComplex.\u003C\u002Fp>\n\n\u003Cp>d. For \u003Cstrong>(b)(4)\u003C\u002Fstrong> you do not have specifications to ensure the purity, strength, and composition of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the Chromium Picolinate dietary supplement.\u003C\u002Fp>\n\n\u003Cp>e. For Calcium Pyruvate you do not have specifications to ensure the purity, strength, and composition of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of Calcium Pyruvate.\u003C\u002Fp>\n\n\u003Cp>In addition to establishing these specifications, you must determine whether such specifications are met, in accordance with 21 CFR 111.73 and 111.75.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated December 7 ,2023, which included revised specifications for the ingredients Calcium Pyruvate, \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and finished product specifications for Chromium Picolinate, CalComplex, and Calcium Pyruvate. Your revised specifications do not meet the requirements of 21 CFR 111.70(b)(2) in that they do not include appropriate specifications to ensure the purity and composition of Chromium Picolinate, Calcium Pyruvate and CalComplex.\u003C\u002Fp>\n\n\u003Cp>3. Your quality control approved and released for distribution a batch of dietary supplement for which a component in the batch did not meet its identity specification, as required by 21 CFR 111.123(b)(1). Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Analytical\u002FChemical Certificate of Analysis dated 9\u002F23\u002F22 for Calcium Pyruvate Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> includes an out-of-specification result of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Calcium. The specification is \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The ingredient was used in the manufacture of Calcium Pyruvate Lot 150822 on 9\u002F9\u002F22, which was prior to testing. Your quality control approved and released the batch on 10\u002F21\u002F22.\u003C\u002Fp>\n\n\u003Cp>4. Your quality control operations failed to approve and release all components from quarantine before they are used in the manufacture of a dietary supplement, as required by 21 CFR 111.120(e). Specifically, you used the following components in manufacture before your quality control personnel approved and released them from quarantine:\u003C\u002Fp>\n\n\u003Cp>a. You used Aquamin F Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 6\u002F28\u002F23 in the manufacture of CalComplex Lot 523008; however, the dietary ingredient was not approved and released from quarantine until 10\u002F10\u002F23.\u003C\u002Fp>\n\n\u003Cp>b. You used Calcium Pyruvate Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 9\u002F8\u002F22 in the manufacture of Calcium Pyruvate Lot 150822; however, the dietary ingredient was not approved and released from quarantine until 9\u002F26\u002F22.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated December 7 ,2023, in which you state you investigated and concluded that personnel turnover and insufficient training was the most probable cause of the component’s documented release timing delay. Additionally, you state CalComplex Lot 523008 and Calcium Pyruvate Lot 150822 met all strength claims. You provided finished product strength test results for CalComplex Lot 523008 and Calcium Pyruvate Lot 150822, updated procedure 12-D-01 (Raw material Component Identity Testing), and staff training records; however, you did not provide documentation to support that your quality control operations are approving and releasing from quarantine all components before use in the manufacture of a dietary supplement.\u003C\u002Fp>\n\n\u003Cp>5. Your quality control operations failed to approve for release, or reject, any packaged and labeled dietary supplements for distribution, as required by 21 CFR 111.127(h). Specifically, your distribution records show that your quality control signed and released Chromium Picolinate Lot 40223 on 7\u002F18\u002F2023, after the finished dietary supplement was shipped on 6\u002F19\u002F2023. Your distribution records further show that your quality control signed and released CalComplex Lot 523008 on 8\u002F22\u002F2023, after the finished dietary supplement was shipped on 8\u002F9\u002F2023.\u003Cbr>\n\u003Cbr>\nWe have reviewed your response dated December 7, 2023, in which you state there was confusion and disorganization of the batch records which unintentionally led to unexpected timing gaps between shipping to the client and your formal material release paperwork. You also provided your updated procedure 12-E-01 Testing and Release of Finished Product, training records, and updated disposition records for Chromium Picolinate Lot 40223 and CalComplex Lot 523008. However, you did not provide documentation to support that you are distributing finished dietary supplements only after approval and release by your quality control unit.\u003C\u002Fp>\n\n\u003Cp>6. You failed to prepare and follow master manufacturing records that include written instructions that include specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record, and specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record, as required by 21 CFR 111.205 and 21 CFR 111.210(h)(1) and (h)(3). Specifically, your manufacturing records for CalComplex, Calcium Pyruvate, and Chromium Picolinate do not include written instructions for manufacturing, packaging, and labeling steps, nor do the records identify those points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated December 7 ,2023, in which you provided revised MMR templates for the CalComplex, Calcium Pyruvate, and Chromium Picolinate. However, we are unable to fully evaluate your proposed corrective actions because you did not provide documentation demonstrating that you have implemented and are following your corrective action in the master manufacturing records for a manufactured batch of CalComplex, Calcium Pyruvate, and Chromium Picolinate.\u003C\u002Fp>\n\n\u003Cp>7. Your batch production record failed to include all information required by 21 CFR 111.260. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. Batch production records for Calcium Pyruvate Lot 150822, Chromium Picolinate Lot 40223, and CalComplex Lot 523008 failed to include a statement of the actual yield at appropriate phases of the processing, as required by 21 CFR 111.260(f);\u003C\u002Fp>\n\n\u003Cp>b. Batch production records for Calcium Pyruvate Lot 150822, Chromium Picolinate Lot 40223, and CalComplex Lot 523008 failed to include the identity of each component used, as required by 21 CFR 111.260(e). For example, the Master Formula page for Calcium Pyruvate Lot 150822 has the weigh out of each component that totals \u003Cstrong>(b)(4)\u003C\u002Fstrong>; however, there is a \u003Cstrong>(b)(4)\u003C\u002Fstrong> set of weights \u003Cstrong>(b)(4)\u003C\u002Fstrong> that does not have the identity of the component documented;\u003Cbr>\n\u003Cbr>\nc. Batch production records for Calcium Pyruvate Lot 150822, Chromium Picolinate Lot 40223, and CalComplex Lot 523008 failed to include an actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the master manufacturing record, as required by 21 CFR 111.260(k)(2);\u003C\u002Fp>\n\n\u003Cp>d. Batch production records did not include documentation at the time of performance that quality control personnel reviewed the batch production records, as required by 21 CFR 111.260(l)(1). Specifically, for Chromium Picolinate Lot 40223, there was no quality review sign off for labeling and packaging materials. For CalComplex Lot 523008 there was no quality review sign off for labeling materials.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated December 7 ,2023. Your response includes updated BPRs. However, we are unable to further evaluate your response since it did not include any evidence that you have implemented the proposed corrective actions in executed batch production records.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>In addition, we reviewed product labels collected during the inspection and have determined the Calcium Pyruvate, Chromium Picolinate, and Calcium Complex Formula #3 (CalComplex) products you manufacture are misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\u003C\u002Fp>\n\n\u003Cp>1. The Calcium Pyruvate and Chromium Picolinate products are misbranded within the meaning of section 403(y) of the Act [21 U.S.C. § 343(y)] in that the labels fail to bear a domestic address or domestic phone number through which the responsible person, as described in section 761 of the Act [21 U.S.C. 379aa-1] may receive a report of a serious adverse event with such dietary supplement.\u003C\u002Fp>\n\n\u003Cp>2. The CalComplex, Calcium Pyruvate, and Chromium Picolinate products are misbranded within the meaning of section 403 (q)(5)(F) of the Act (21 U.S.C. 343(q)(5)(F)) in that the presentation of the nutrition information on the labeling of these products does not comply with 21 CFR 101.36 and 101.9. For example:\u003C\u002Fp>\n\n\u003Cp>a. For the CalComplex product:\u003Cbr>\n&nbsp; i. The presentation of the (b)(2)-dietary ingredients is not in the order as set forth in 21 CFR 101.36(b)(2)(i)(B). For example, the declaration of calcium must appear before the declaration of phosphorus.\u003C\u002Fp>\n\n\u003Cp>b. For your Calcium Pyruvate product:\u003Cbr>\n&nbsp; i. The title, “Supplement Facts”, is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(b)(1)(i).\u003Cbr>\n&nbsp; ii. The label lists calcium pyruvate which is not the nomenclature specified for calcium in 21 CFR 101.9(c)(8) or 21 CFR 101.36(b)(2). The source ingredient that supplies a dietary ingredient may be identified within the nutrition label in parentheses immediately following or indented beneath the name of a dietary ingredient and preceded by the words \"as\" or \"from\", e.g., \"Calcium (as calcium pyruvate)\". When a source ingredient is not identified within the nutrition label, it shall be listed in an ingredient statement [21 CFR 101.36(d)].\u003Cbr>\n&nbsp; iii. The Supplement Facts label must list the % Daily Value for (b)(2)-dietary ingredients by calculating the dietary ingredient’s quantitative amount by weight per serving divided by the established RDI noted in 21 CFR 101.9(c)(8)(iv), and expressed to the nearest whole percent, in accordance with 21 CFR 101.36(b)(2)(iii)(B).\u003Cbr>\n&nbsp; iv. The Supplement Facts label format requirements including the use of bolded text, hairlines, and\u002For light and heavy bars are not in accordance with 21 CFR 101.36(e).\u003C\u002Fp>\n\n\u003Cp>c. For the Chromium Picolinate product:\u003Cbr>\n&nbsp; i. The title, “Supplement Facts”, is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(b)(1)(i).\u003Cbr>\n&nbsp; ii. The Supplement Facts label must list the % Daily Value for (b)(2)-dietary ingredients by calculating the dietary ingredient’s quantitative amount by weight per serving divided by the established RDI noted in 21 CFR 101.9(c)(8)(iv), and expressed to the nearest whole percent, in accordance with 21 CFR 101.36(b)(2)(iii)(B).\u003Cbr>\n&nbsp; iii. The Supplement Facts label format requirements including the use of bolded text, hairlines, and\u002For light and heavy bars are not in accordance with 21 CFR 101.36(e).\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>We also have the following comments:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>For the CalComplex product, the statement “Allergen Warning” appears before the Contains statement, which is considered intervening material.\u003C\u002Fli>\n\t\u003Cli>We note that the CalComplex product declares “Naticol Marine Collagen.” Naticol’s website at https:\u002F\u002Fwww.naticol.com\u002Fen\u002Fnaticol-en\u002F describes their ingredients as “a range of bioactive and bioavailable marine collagen peptides of natural origin.” If the dietary ingredient used in this product is marine peptides, that ingredient must be declared by its common or usual name.\u003C\u002Fli>\n\t\u003Cli>For the Cal Complex product, “Aquamin™” is not the common or usual name for&nbsp;\u003Cem>Lithothamnion\u003C\u002Fem> spp.\u003C\u002Fli>\n\t\u003Cli>For the Calcium Pyruvate product, the statement “**Daily Value not Established” must bewithin the Supplements Facts label.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be directed to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\nLos Angeles District Office\u003Cbr>\n19701 Fairchild\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>or emailed to ORAHAFWEST5FirmResponses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Refer to the Unique Identification Number CMS 672954 when replying.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding this letter, please contact Rochelle R. Blair, Compliance Officer at rochelle.blair@FDA.hhs.gov, or (949) 608-4496.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nDarla R. Bracy\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations- West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nRobert P. Bailly\n\nRecipient Title\n\nActing CEO\n\nWest Coast Laboratories, Inc.\n\n116 E. Alondra Blvd.\n\nGardena, CA 90248-2806\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nWARNING LETTER\n\nJune 12, 2024\n\nWL 672954\n\nDear Mr. Bailly:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your facility located at 116 E. Alondra Blvd., Gardena, CA from October 3 through October 24, 2023. Based on the inspectional findings we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on the FDA’s home page at http:\u002F\u002Fwww.fda.gov.\n\nAt the conclusion of the inspection on October 24, 2023, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your written responses dated November 15, December 1, and December 7, 2023. Your November 15 and December 1, 2023, communications did not address the specific observations. We address your December 7, 2023, response below, where relevant.\n\nAdulterated Dietary Supplements\n\nThe inspection of your facility from October 3, 2023, through October 24, 2023, identified serious violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the Calcium Pyruvate, Chromium Picolinate, and CalComplex products manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\n\nYour significant violations of the CGMP requirements are as follows:\n\n1. You did not conduct at least one appropriate test or examination to verify the identity of a dietary ingredient, prior to its use, as required by 21 CFR 111.75(a)(1)(i), nor did you petition the agency under 21 CFR 111.75(a)(1)(ii) for exemption from such testing.\n\nSpecifically, you did not conduct identity testing for (b)(4) Lot (b)(4), Naticol HPMG Lot (b)(4), and Aquamin F (b)(4) used in the manufacture of CalComplex Lot 523008; you did not conduct identity testing for (b)(4) Lot (b)(4) used in the manufacture of Chromium Picolinate Lot 40223; nor did you conduct identity testing for Calcium Pyruvate Lots (b)(4) or Lot (b)(4) used in the manufacture of Calcium Pyruvate Lot 150822. You also have not petitioned the agency for an exemption for such testing.\n\nWe have reviewed your response dated December 7 ,2023, in which you provided revised raw material specifications for Aquamin F, Calcium Pyruvate, (b)(4), and Naticol HPMG. Each of these documents purports to establish a specification of more than (b)(4) match by FTIR. However, you did not provide test records to support that you are conducting identity testing in accordance with the established identity specifications for each of these components.\n\n2. You failed to establish component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically:\n\na. For (b)(4) you do not have specifications to ensure the purity, strength, and composition of the (b)(4) and (b)(4) used in the manufacture of CalComplex.\n\nb. For Naticol HPMG you do not have specifications to ensure the purity, strength, and composition of proteins used in the manufacture of CalComplex.\n\nc. For Aquamin F you do not have specifications to ensure the purity, strength, and composition of (b)(4) used in the manufacture of CalComplex.\n\nd. For (b)(4) you do not have specifications to ensure the purity, strength, and composition of (b)(4) used in the Chromium Picolinate dietary supplement.\n\ne. For Calcium Pyruvate you do not have specifications to ensure the purity, strength, and composition of (b)(4) used in the manufacture of Calcium Pyruvate.\n\nIn addition to establishing these specifications, you must determine whether such specifications are met, in accordance with 21 CFR 111.73 and 111.75.\n\nWe have reviewed your response dated December 7 ,2023, which included revised specifications for the ingredients Calcium Pyruvate, (b)(4); and finished product specifications for Chromium Picolinate, CalComplex, and Calcium Pyruvate. Your revised specifications do not meet the requirements of 21 CFR 111.70(b)(2) in that they do not include appropriate specifications to ensure the purity and composition of Chromium Picolinate, Calcium Pyruvate and CalComplex.\n\n3. Your quality control approved and released for distribution a batch of dietary supplement for which a component in the batch did not meet its identity specification, as required by 21 CFR 111.123(b)(1). Specifically, (b)(4) Analytical\u002FChemical Certificate of Analysis dated 9\u002F23\u002F22 for Calcium Pyruvate Lot (b)(4) includes an out-of-specification result of (b)(4) for Calcium. The specification is (b)(4). The ingredient was used in the manufacture of Calcium Pyruvate Lot 150822 on 9\u002F9\u002F22, which was prior to testing. Your quality control approved and released the batch on 10\u002F21\u002F22.\n\n4. Your quality control operations failed to approve and release all components from quarantine before they are used in the manufacture of a dietary supplement, as required by 21 CFR 111.120(e). Specifically, you used the following components in manufacture before your quality control personnel approved and released them from quarantine:\n\na. You used Aquamin F Lot (b)(4) on 6\u002F28\u002F23 in the manufacture of CalComplex Lot 523008; however, the dietary ingredient was not approved and released from quarantine until 10\u002F10\u002F23.\n\nb. You used Calcium Pyruvate Lot (b)(4) on 9\u002F8\u002F22 in the manufacture of Calcium Pyruvate Lot 150822; however, the dietary ingredient was not approved and released from quarantine until 9\u002F26\u002F22.\n\nWe have reviewed your response dated December 7 ,2023, in which you state you investigated and concluded that personnel turnover and insufficient training was the most probable cause of the component’s documented release timing delay. Additionally, you state CalComplex Lot 523008 and Calcium Pyruvate Lot 150822 met all strength claims. You provided finished product strength test results for CalComplex Lot 523008 and Calcium Pyruvate Lot 150822, updated procedure 12-D-01 (Raw material Component Identity Testing), and staff training records; however, you did not provide documentation to support that your quality control operations are approving and releasing from quarantine all components before use in the manufacture of a dietary supplement.\n\n5. Your quality control operations failed to approve for release, or reject, any packaged and labeled dietary supplements for distribution, as required by 21 CFR 111.127(h). Specifically, your distribution records show that your quality control signed and released Chromium Picolinate Lot 40223 on 7\u002F18\u002F2023, after the finished dietary supplement was shipped on 6\u002F19\u002F2023. Your distribution records further show that your quality control signed and released CalComplex Lot 523008 on 8\u002F22\u002F2023, after the finished dietary supplement was shipped on 8\u002F9\u002F2023.\n\nWe have reviewed your response dated December 7, 2023, in which you state there was confusion and disorganization of the batch records which unintentionally led to unexpected timing gaps between shipping to the client and your formal material release paperwork. You also provided your updated procedure 12-E-01 Testing and Release of Finished Product, training records, and updated disposition records for Chromium Picolinate Lot 40223 and CalComplex Lot 523008. However, you did not provide documentation to support that you are distributing finished dietary supplements only after approval and release by your quality control unit.\n\n6. You failed to prepare and follow master manufacturing records that include written instructions that include specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record, and specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the master manufacturing record, as required by 21 CFR 111.205 and 21 CFR 111.210(h)(1) and (h)(3). Specifically, your manufacturing records for CalComplex, Calcium Pyruvate, and Chromium Picolinate do not include written instructions for manufacturing, packaging, and labeling steps, nor do the records identify those points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement.\n\nWe have reviewed your response dated December 7 ,2023, in which you provided revised MMR templates for the CalComplex, Calcium Pyruvate, and Chromium Picolinate. However, we are unable to fully evaluate your proposed corrective actions because you did not provide documentation demonstrating that you have implemented and are following your corrective action in the master manufacturing records for a manufactured batch of CalComplex, Calcium Pyruvate, and Chromium Picolinate.\n\n7. Your batch production record failed to include all information required by 21 CFR 111.260. Specifically:\n\na. Batch production records for Calcium Pyruvate Lot 150822, Chromium Picolinate Lot 40223, and CalComplex Lot 523008 failed to include a statement of the actual yield at appropriate phases of the processing, as required by 21 CFR 111.260(f);\n\nb. Batch production records for Calcium Pyruvate Lot 150822, Chromium Picolinate Lot 40223, and CalComplex Lot 523008 failed to include the identity of each component used, as required by 21 CFR 111.260(e). For example, the Master Formula page for Calcium Pyruvate Lot 150822 has the weigh out of each component that totals (b)(4); however, there is a (b)(4) set of weights (b)(4) that does not have the identity of the component documented;\n\nc. Batch production records for Calcium Pyruvate Lot 150822, Chromium Picolinate Lot 40223, and CalComplex Lot 523008 failed to include an actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the master manufacturing record, as required by 21 CFR 111.260(k)(2);\n\nd. Batch production records did not include documentation at the time of performance that quality control personnel reviewed the batch production records, as required by 21 CFR 111.260(l)(1). Specifically, for Chromium Picolinate Lot 40223, there was no quality review sign off for labeling and packaging materials. For CalComplex Lot 523008 there was no quality review sign off for labeling materials.\n\nWe have reviewed your response dated December 7 ,2023. Your response includes updated BPRs. However, we are unable to further evaluate your response since it did not include any evidence that you have implemented the proposed corrective actions in executed batch production records.\n\nMisbranded Dietary Supplements\n\nIn addition, we reviewed product labels collected during the inspection and have determined the Calcium Pyruvate, Chromium Picolinate, and Calcium Complex Formula #3 (CalComplex) products you manufacture are misbranded under section 403 of the Act [21 U.S.C. 343] because they do not comply with the labeling requirements for dietary supplements. Specifically, we identified the following:\n\n1. The Calcium Pyruvate and Chromium Picolinate products are misbranded within the meaning of section 403(y) of the Act [21 U.S.C. § 343(y)] in that the labels fail to bear a domestic address or domestic phone number through which the responsible person, as described in section 761 of the Act [21 U.S.C. 379aa-1] may receive a report of a serious adverse event with such dietary supplement.\n\n2. The CalComplex, Calcium Pyruvate, and Chromium Picolinate products are misbranded within the meaning of section 403 (q)(5)(F) of the Act (21 U.S.C. 343(q)(5)(F)) in that the presentation of the nutrition information on the labeling of these products does not comply with 21 CFR 101.36 and 101.9. For example:\n\na. For the CalComplex product:\n\ni. The presentation of the (b)(2)-dietary ingredients is not in the order as set forth in 21 CFR 101.36(b)(2)(i)(B). For example, the declaration of calcium must appear before the declaration of phosphorus.\n\nb. For your Calcium Pyruvate product:\n\ni. The title, “Supplement Facts”, is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(b)(1)(i).\n\nii. The label lists calcium pyruvate which is not the nomenclature specified for calcium in 21 CFR 101.9(c)(8) or 21 CFR 101.36(b)(2). The source ingredient that supplies a dietary ingredient may be identified within the nutrition label in parentheses immediately following or indented beneath the name of a dietary ingredient and preceded by the words \"as\" or \"from\", e.g., \"Calcium (as calcium pyruvate)\". When a source ingredient is not identified within the nutrition label, it shall be listed in an ingredient statement [21 CFR 101.36(d)].\n\niii. The Supplement Facts label must list the % Daily Value for (b)(2)-dietary ingredients by calculating the dietary ingredient’s quantitative amount by weight per serving divided by the established RDI noted in 21 CFR 101.9(c)(8)(iv), and expressed to the nearest whole percent, in accordance with 21 CFR 101.36(b)(2)(iii)(B).\n\niv. The Supplement Facts label format requirements including the use of bolded text, hairlines, and\u002For light and heavy bars are not in accordance with 21 CFR 101.36(e).\n\nc. For the Chromium Picolinate product:\n\ni. The title, “Supplement Facts”, is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(b)(1)(i).\n\nii. The Supplement Facts label must list the % Daily Value for (b)(2)-dietary ingredients by calculating the dietary ingredient’s quantitative amount by weight per serving divided by the established RDI noted in 21 CFR 101.9(c)(8)(iv), and expressed to the nearest whole percent, in accordance with 21 CFR 101.36(b)(2)(iii)(B).\n\niii. The Supplement Facts label format requirements including the use of bolded text, hairlines, and\u002For light and heavy bars are not in accordance with 21 CFR 101.36(e).\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWe also have the following comments:\n\nFor the CalComplex product, the statement “Allergen Warning” appears before the Contains statement, which is considered intervening material.\n\nWe note that the CalComplex product declares “Naticol Marine Collagen.” Naticol’s website at https:\u002F\u002Fwww.naticol.com\u002Fen\u002Fnaticol-en\u002F describes their ingredients as “a range of bioactive and bioavailable marine collagen peptides of natural origin.” If the dietary ingredient used in this product is marine peptides, that ingredient must be declared by its common or usual name.\n\nFor the Cal Complex product, “Aquamin™” is not the common or usual name for Lithothamnion spp.\n\nFor the Calcium Pyruvate product, the statement “**Daily Value not Established” must bewithin the Supplements Facts label.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be directed to:\n\nSergio Chavez, Director Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\nLos Angeles District Office\n\n19701 Fairchild\n\nIrvine, CA 92612\n\nor emailed to ORAHAFWEST5FirmResponses@fda.hhs.gov.\n\nRefer to the Unique Identification Number CMS 672954 when replying.\n\nIf you have questions regarding this letter, please contact Rochelle R. Blair, Compliance Officer at rochelle.blair@FDA.hhs.gov, or (949) 608-4496.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations- West Division 5","West Coast Laboratories, Inc.","west-coast-laboratories-inc-672954-06122024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwest-coast-laboratories-inc-672954-06122024","2026-10-26T08:10:31.108477+00:00","2024-07-23","672954","Dietary Supplements","Robert P. Bailly","2026-08-19T23:57:04.117+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED",{"id":139,"raw":140,"subject":145,"body_html":146,"body_text":147,"firm_name":148,"letter_id":149,"created_at":150,"fei_number":20,"letter_url":151,"updated_at":152,"action_type":23,"case_status":48,"posted_date":153,"marcs_cms_no":154,"product_type":51,"closeout_date":20,"issuing_office":125,"recipient_name":155,"body_fetched_at":156,"delivery_method":157,"recipient_title":20,"reference_number":20,"action_taken_date":158,"medical_device_id":20,"response_letter_date":20},2275,[141,142,143,144,145,13,13,13],"\u003Ctime datetime=\"2022-12-27T14:20:00Z\">12\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-28T05:00:00Z\">11\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbainbridge-beverage-west-llc-638942-11282022\">Bainbridge Beverage West, LLC\u003C\u002Fa>"," Division of Human and Animal Food Operations West V","Juice HACCP\u002FCGMP for Foods\u002FAdulterated\u002FInsanitary Conditions","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Sarah A. Jollay\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Bainbridge Beverage West, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2335 Del Monte Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>West Sacramento\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95691-3806\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nWL 638942\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Jollay:\u003C\u002Fp>\n\n\u003Cp>The U.S Food and Drug Administration (FDA) inspected your juice manufacturing facility, located at 2335 Del Monte Street, West Sacramento, CA 95691 on June 9, 10, 22, 24, and 29, 2022. We found that you have serious violations of the FDA’s juice Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 120 (21 CFR Part 120). In accordance with 21 CFR 120.9, failure of a processor to have and implement a HACCP plan that complies with the requirements of 21 CFR Part 120 renders the juice products adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)]. Accordingly, your juice products are adulterated in that they have been prepared, packed, or held under insanitary conditions whereby they may have been contaminated with filth, or whereby they may have been rendered injurious to health. You may find the Act, FDA’s juice HACCP regulations and the Juice HACCP Hazards and Controls Guidance through links in FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>To date, the agency has not received a written response from your firm regarding the violations noted on the Form FDA-483, Inspectional Observations, which was issued to your firm at the conclusion of the inspection.\u003C\u002Fp>\n\n\u003Cp>The significant violations include the following:\u003C\u002Fp>\n\n\u003Cp>1. You did not validate that your HACCP plan is adequate to control food hazards when a change in the process occurred that could have affected the hazard analysis or altered the HACCP plan in any way, as required by 21 CFR 120.11(b).\u003Cbr>\n\u003Cbr>\nYou were informed on June 1, 2022, that organic fresh strawberries (from “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”) that you received were potentially contaminated with hepatitis A. You used these strawberries in the juice products \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>During the inspection at your facility on June 9, 2022, you stated that after being notified of the potentially contaminated strawberries, you reviewed your production records to verify the implicated strawberries received were used only in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> juices. You also notified your processor who applies high pressure processing (HPP) as a treatment to produce the required minimum 5-log reduction, and you notified the produce supplier of the use of these strawberries in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> products.\u003C\u002Fp>\n\n\u003Cp>Your Hazard Analysis and HACCP plan for “Cold Pressed Beverages,” dated September 30, 2021, did not identify hepatitis A as a hazard. In addition, your customer’s HPP process validation study that covers the juice products does not cover hepatitis A. However, you did not validate your HACCP plan before manufacturing subsequent lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>You did not evaluate\u002Freassess the applicable HPP validation studies and critical limits after being notified, to determine if they were adequate to control for hepatitis A.\u003C\u002Fli>\n\t\u003Cli>You did not evaluate\u002Freassess the effectiveness of your sanitation procedures to address the potential for cross contamination to other products. Your sanitation procedures for processing equipment such as the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and batch tanks only included a \u003Cstrong>(b)(4)\u003C\u002Fstrong> rinse between pressing different fruits and vegetables and between processing different juices.\u003C\u002Fli>\n\t\u003Cli>You did not reassess your strawberry supplier to determine if you should discontinue use or implement additional measures at receiving. You received additional shipments containing strawberries from the same supplier on June 6, 2022 and June 27, 2022.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>2. Your written hazard analysis does not consist of an identification of food hazards and an identification of the control measures that can be applied, as required by 21 CFR 120.7(a).\u003C\u002Fp>\n\n\u003Cp>a) Your hazard analysis for “Cold Pressed Beverages,” dated September 30, 2021, identifies “Vegetative pathogens (Listeria, Salmonella, E. coli)” as potential hazards but does not identify any control measures to produce the required minimum 5-log reduction in the pertinent microorganism(s) in any of the juices and juice-based beverages that it covers.\u003Cbr>\nb) You use fresh apples and frozen unpasteurized not from concentrate (NFC) apple juice in several of your blended juices\u002Fjuice products. You have not identified Cryptosporidium parvum as a food hazard in your hazard analysis for your apple juice products. Also, you have not identified any controls for the hazard. Furthermore, the associated HPP validation study which was used to establish the critical limits for HPP processing only considered Listeria, E. coli O157:H7 and Salmonella spp. You manufactured “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>?” juice product using fresh apples on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>3. You must monitor the conditions and practices during processing with sufficient frequency to ensure, at a minimum, conformance with the current good manufacturing practice requirements in 21 CFR 117, Subpart B (CGMPs), that are both appropriate to your plant and the food being processed and relate to one of the areas specified in 21 CFR 120.6(a)(1)-(8), to comply with 21 CFR 120.6(b).\u003C\u002Fp>\n\n\u003Cp>However, on June 9, 2022 you failed to monitor the conditions and practices during processing with sufficient frequency to ensure, at a minimum, conformance with CGMPs in the following areas:\u003C\u002Fp>\n\n\u003Cp>A. You failed to monitor handwashing with sufficient frequency to ensure that hands are washed thoroughly at any time when the hands may have become soiled or contaminated, as required by 21 CFR 117.10(b)(3). This is related to prevention of cross contamination from insanitary objects to food, 21 CFR 120.6(a)(3).\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. The employee who was setting up\u002Fassembling the \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not change gloves or wash hands prior to loading the conveyor at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with celery stalks for the product, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003Cbr>\n&nbsp; ii. The production manager did not wash his hands prior to donning gloves to enter production area to set up\u002Fstage bottles for the filler line. He put the disposable gloves over the cloth gloves he was wearing. He then grabbed these bottles to load the conveyor from the mouth of the bottle where his gloved fingers were touching the inside of the bottle.\u003C\u002Fp>\n\n\u003Cp>B. You failed to monitor the conditions and practices during processing with sufficient frequency to ensure that building, fixtures, and other physical facilities of the plant are maintained in a clean and sanitary condition as required by 21 CFR 117.35(a). This is related to prevention of cross contamination from insanitary objects to food, 21 CFR 120.6(a)(3).\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. An employee at the blending station used the employee hand washing station by the blending station to rinse a small bowl and a whisk used for mixing \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the products, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003Cbr>\n&nbsp; ii. A small plastic trash can for employees to dispose of gloves and paper towels at the hand washing station near the blending station was overfilled with trash. Strawberries were observed all over the floor around the trash can and red spots identified as liquid from discarded frozen strawberries were observed on the gloves located at the handwashing station. These gloves are for employee use during production.\u003Cbr>\n&nbsp; iii. There was an open ceiling tile above the filler line where uncapped bottles were being conveyed to a carousel table.\u003Cbr>\n&nbsp; iv. There was heavy dust build-up on power cords hanging off the ceiling above the open \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the open \u003Cstrong>(b)(4)\u003C\u002Fstrong> that were in use.\u003Cbr>\n&nbsp; v. There was a rusty pipe located directly above the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>4. You did not maintain sanitation standard operating procedure (SSOP) records that document the monitoring and corrections of conditions and practices during processing, as required per 21 CFR 120.6(c).\u003C\u002Fp>\n\n\u003Cp>a) Your “Food Allergen Control” SOP BQP-03-D, states under the Sanitation section as follows: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\n\n\u003Cp>The production records for April 28, 2022 show you used staging tank \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the filler line to fill bottles of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” product, which contains coconut water. The record shows that the following products that do not contain coconut were filled on the filler line after “\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;at \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;at \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The “FILLER START-UP\u002FCHANGEOVER CHECKLIST” used for monitoring the filler includes a box to be checked to “Verify Filler is Cleaned.” The form does not include fields to document the criteria (e.g., chemical concentration, temperature and time for treatments) required per your “Food Allergen Control” procedure. You stated you do not keep other records for monitoring the sanitation process between product changeovers.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you stated you conduct a verification step by collecting swabs to test for coconut allergen after cleaning and sanitation and prior to producing the next product without the coconut allergen. However, your “ALLERGEN TESTING LOCATIONS” record dated April 28, 2022, shows that swabbing was completed at \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This time does not correspond with the production records that indicate at \u003Cstrong>(b)(4)\u003C\u002Fstrong> your firm had already started filling the next product, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\n\n\u003Cp>b) You do not maintain SSOP monitoring records for employee health conditions that could result in the microbial contamination of food.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Comments:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You use \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” juice products. You identified the ingredient as a spice in your “Cold Pressed Beverages HACCP Plan.” In evaluating which food hazards are reasonably likely to occur, you did not consider the unapproved use of food or color additives as required per 21 CFR 120.7(c). There is no regulation in 21 Code of Federal Regulation that permits the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a direct food additive or color additive, and we are not aware of a basis to conclude its use as an ingredient in food would be generally recognized as safe by qualified experts. Activated carbon is allowed for use in the manufacture of closure-sealing gaskets for food containers per 21 CFR 177.1210; however, this is not applicable to your products as the \u003Cstrong>(b)(4)\u003C\u002Fstrong> is directly added as an ingredient. Further, you have not assessed \u003Cstrong>(b)(4)\u003C\u002Fstrong> for safety. Your ingredient supplier’s \u003Cstrong>(b)(4)\u003C\u002Fstrong> product label states, “Do not consume at the same time as any medicines or other dietary supplement, as this may interfere with their effectiveness.” FDA has evaluated the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> as an emetic poison treatment drug. Our review found that while it may be used in high doses, it can adsorb other nutrients or medications; therefore, it can interfere with the consumer’s medications or dietary needs. Additionally, \u003Cstrong>(b)(4)\u003C\u002Fstrong> can contain carcinogenic polyaromatic hydrocarbons and unsafe levels of heavy metals. Little is known about the safety of chronic consumption of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>If your use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> imparts color to these beverages, it meets the statutory definition of a color additive at section 201(t) of the FD&amp;C Act [21 U.S.C. § 321(t)]. Color additives are deemed unsafe unless their use conforms with a regulation listing the color additive and describing the conditions for its safe use (section 721(a) of the FD&amp;C Act) [21 U.S.C. § 379e(a)]. There is no regulation authorizing use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a color additive in food. Food that contains an unapproved color additive is deemed adulterated (section 402(c) of the FD&amp;C Act) [21 U.S.C. § 342(c)].\u003C\u002Fp>\n\n\u003Cp>The violations in this letter are not intended to be an all-inclusive list of the violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to address the violations noted in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within 15 working days of the receipt of this letter as to the specific steps you have taken to address these violations, including an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. In your response, you should include documentation, including revised procedures, photographs, results of tests you have conducted, and other useful information that would assist us in evaluating your corrections. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director, Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\n1201 Harbor Bay Parkway\u003Cbr>\nAlameda, CA 94502\u003C\u002Fp>\n\n\u003Cp>Refer to Unique Identification Number CMS# 638942 when replying.\u003C\u002Fp>\n\n\u003Cp>If you prefer to send your response electronically, please email it to: ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and CMS# 638942 number in the title of the e-mail message.\u003C\u002Fp>\n\n\u003Cp>If you have any questions regarding this letter, please contact Kimberly M. Lichter, Compliance Officer, at kimberly.lichter@fda.hhs.gov or (949) 608-2967.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nDistrict Director | FDA San Francisco District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations – West Division 5\u003Cbr>\n\u003Cbr>\nCC: Bainbridge Beverage West, LLC\u003Cbr>\nPO Box 938\u003Cbr>\nColoma, MI 49038-0938\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMs. Sarah A. Jollay\n\nRecipient Title\n\nCEO\n\nBainbridge Beverage West, LLC\n\n2335 Del Monte Street\n\nWest Sacramento, CA 95691-3806\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nWARNING LETTER\n\nWL 638942\n\nDear Ms. Jollay:\n\nThe U.S Food and Drug Administration (FDA) inspected your juice manufacturing facility, located at 2335 Del Monte Street, West Sacramento, CA 95691 on June 9, 10, 22, 24, and 29, 2022. We found that you have serious violations of the FDA’s juice Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 120 (21 CFR Part 120). In accordance with 21 CFR 120.9, failure of a processor to have and implement a HACCP plan that complies with the requirements of 21 CFR Part 120 renders the juice products adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)]. Accordingly, your juice products are adulterated in that they have been prepared, packed, or held under insanitary conditions whereby they may have been contaminated with filth, or whereby they may have been rendered injurious to health. You may find the Act, FDA’s juice HACCP regulations and the Juice HACCP Hazards and Controls Guidance through links in FDA’s home page at www.fda.gov.\n\nTo date, the agency has not received a written response from your firm regarding the violations noted on the Form FDA-483, Inspectional Observations, which was issued to your firm at the conclusion of the inspection.\n\nThe significant violations include the following:\n\n1. You did not validate that your HACCP plan is adequate to control food hazards when a change in the process occurred that could have affected the hazard analysis or altered the HACCP plan in any way, as required by 21 CFR 120.11(b).\n\nYou were informed on June 1, 2022, that organic fresh strawberries (from “(b)(4)”) that you received were potentially contaminated with hepatitis A. You used these strawberries in the juice products (b)(4) and (b)(4) manufactured on (b)(4).\n\nDuring the inspection at your facility on June 9, 2022, you stated that after being notified of the potentially contaminated strawberries, you reviewed your production records to verify the implicated strawberries received were used only in the (b)(4) and (b)(4) juices. You also notified your processor who applies high pressure processing (HPP) as a treatment to produce the required minimum 5-log reduction, and you notified the produce supplier of the use of these strawberries in the (b)(4) products.\n\nYour Hazard Analysis and HACCP plan for “Cold Pressed Beverages,” dated September 30, 2021, did not identify hepatitis A as a hazard. In addition, your customer’s HPP process validation study that covers the juice products does not cover hepatitis A. However, you did not validate your HACCP plan before manufacturing subsequent lots of (b)(4) and (b)(4) on (b)(4). For example:\n\nYou did not evaluate\u002Freassess the applicable HPP validation studies and critical limits after being notified, to determine if they were adequate to control for hepatitis A.\n\nYou did not evaluate\u002Freassess the effectiveness of your sanitation procedures to address the potential for cross contamination to other products. Your sanitation procedures for processing equipment such as the (b)(4) and batch tanks only included a (b)(4) rinse between pressing different fruits and vegetables and between processing different juices.\n\nYou did not reassess your strawberry supplier to determine if you should discontinue use or implement additional measures at receiving. You received additional shipments containing strawberries from the same supplier on June 6, 2022 and June 27, 2022.\n\n2. Your written hazard analysis does not consist of an identification of food hazards and an identification of the control measures that can be applied, as required by 21 CFR 120.7(a).\n\na) Your hazard analysis for “Cold Pressed Beverages,” dated September 30, 2021, identifies “Vegetative pathogens (Listeria, Salmonella, E. coli)” as potential hazards but does not identify any control measures to produce the required minimum 5-log reduction in the pertinent microorganism(s) in any of the juices and juice-based beverages that it covers.\n\nb) You use fresh apples and frozen unpasteurized not from concentrate (NFC) apple juice in several of your blended juices\u002Fjuice products. You have not identified Cryptosporidium parvum as a food hazard in your hazard analysis for your apple juice products. Also, you have not identified any controls for the hazard. Furthermore, the associated HPP validation study which was used to establish the critical limits for HPP processing only considered Listeria, E. coli O157:H7 and Salmonella spp. You manufactured “(b)(4)” and “(b)(4)?” juice product using fresh apples on (b)(4).\n\n3. You must monitor the conditions and practices during processing with sufficient frequency to ensure, at a minimum, conformance with the current good manufacturing practice requirements in 21 CFR 117, Subpart B (CGMPs), that are both appropriate to your plant and the food being processed and relate to one of the areas specified in 21 CFR 120.6(a)(1)-(8), to comply with 21 CFR 120.6(b).\n\nHowever, on June 9, 2022 you failed to monitor the conditions and practices during processing with sufficient frequency to ensure, at a minimum, conformance with CGMPs in the following areas:\n\nA. You failed to monitor handwashing with sufficient frequency to ensure that hands are washed thoroughly at any time when the hands may have become soiled or contaminated, as required by 21 CFR 117.10(b)(3). This is related to prevention of cross contamination from insanitary objects to food, 21 CFR 120.6(a)(3).\n\ni. The employee who was setting up\u002Fassembling the (b)(4) did not change gloves or wash hands prior to loading the conveyor at the (b)(4) with celery stalks for the product, “(b)(4).”\n\nii. The production manager did not wash his hands prior to donning gloves to enter production area to set up\u002Fstage bottles for the filler line. He put the disposable gloves over the cloth gloves he was wearing. He then grabbed these bottles to load the conveyor from the mouth of the bottle where his gloved fingers were touching the inside of the bottle.\n\nB. You failed to monitor the conditions and practices during processing with sufficient frequency to ensure that building, fixtures, and other physical facilities of the plant are maintained in a clean and sanitary condition as required by 21 CFR 117.35(a). This is related to prevention of cross contamination from insanitary objects to food, 21 CFR 120.6(a)(3).\n\ni. An employee at the blending station used the employee hand washing station by the blending station to rinse a small bowl and a whisk used for mixing (b)(4) used in the products, “(b)(4)” and “(b)(4).”\n\nii. A small plastic trash can for employees to dispose of gloves and paper towels at the hand washing station near the blending station was overfilled with trash. Strawberries were observed all over the floor around the trash can and red spots identified as liquid from discarded frozen strawberries were observed on the gloves located at the handwashing station. These gloves are for employee use during production.\n\niii. There was an open ceiling tile above the filler line where uncapped bottles were being conveyed to a carousel table.\n\niv. There was heavy dust build-up on power cords hanging off the ceiling above the open (b)(4) and the open (b)(4) that were in use.\n\nv. There was a rusty pipe located directly above the (b)(4).\n\n4. You did not maintain sanitation standard operating procedure (SSOP) records that document the monitoring and corrections of conditions and practices during processing, as required per 21 CFR 120.6(c).\n\na) Your “Food Allergen Control” SOP BQP-03-D, states under the Sanitation section as follows: “(b)(4).”\n\nThe production records for April 28, 2022 show you used staging tank (b)(4) and the filler line to fill bottles of “(b)(4)” product, which contains coconut water. The record shows that the following products that do not contain coconut were filled on the filler line after “(b)(4) at (b)(4) at (b)(4) at (b)(4) at (b)(4). The “FILLER START-UP\u002FCHANGEOVER CHECKLIST” used for monitoring the filler includes a box to be checked to “Verify Filler is Cleaned.” The form does not include fields to document the criteria (e.g., chemical concentration, temperature and time for treatments) required per your “Food Allergen Control” procedure. You stated you do not keep other records for monitoring the sanitation process between product changeovers.\n\nFurthermore, you stated you conduct a verification step by collecting swabs to test for coconut allergen after cleaning and sanitation and prior to producing the next product without the coconut allergen. However, your “ALLERGEN TESTING LOCATIONS” record dated April 28, 2022, shows that swabbing was completed at (b)(4). This time does not correspond with the production records that indicate at (b)(4) your firm had already started filling the next product, “(b)(4).”\n\nb) You do not maintain SSOP monitoring records for employee health conditions that could result in the microbial contamination of food.\n\nAdditional Comments:\n\nYou use (b)(4) in your “(b)(4)” and “(b)(4)” juice products. You identified the ingredient as a spice in your “Cold Pressed Beverages HACCP Plan.” In evaluating which food hazards are reasonably likely to occur, you did not consider the unapproved use of food or color additives as required per 21 CFR 120.7(c). There is no regulation in 21 Code of Federal Regulation that permits the use of (b)(4) as a direct food additive or color additive, and we are not aware of a basis to conclude its use as an ingredient in food would be generally recognized as safe by qualified experts. Activated carbon is allowed for use in the manufacture of closure-sealing gaskets for food containers per 21 CFR 177.1210; however, this is not applicable to your products as the (b)(4) is directly added as an ingredient. Further, you have not assessed (b)(4) for safety. Your ingredient supplier’s (b)(4) product label states, “Do not consume at the same time as any medicines or other dietary supplement, as this may interfere with their effectiveness.” FDA has evaluated the use of (b)(4) as an emetic poison treatment drug. Our review found that while it may be used in high doses, it can adsorb other nutrients or medications; therefore, it can interfere with the consumer’s medications or dietary needs. Additionally, (b)(4) can contain carcinogenic polyaromatic hydrocarbons and unsafe levels of heavy metals. Little is known about the safety of chronic consumption of (b)(4).\n\nIf your use of (b)(4) imparts color to these beverages, it meets the statutory definition of a color additive at section 201(t) of the FD&C Act [21 U.S.C. § 321(t)]. Color additives are deemed unsafe unless their use conforms with a regulation listing the color additive and describing the conditions for its safe use (section 721(a) of the FD&C Act) [21 U.S.C. § 379e(a)]. There is no regulation authorizing use of (b)(4) as a color additive in food. Food that contains an unapproved color additive is deemed adulterated (section 402(c) of the FD&C Act) [21 U.S.C. § 342(c)].\n\nThe violations in this letter are not intended to be an all-inclusive list of the violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to address the violations noted in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\n\nPlease notify this office in writing within 15 working days of the receipt of this letter as to the specific steps you have taken to address these violations, including an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. In your response, you should include documentation, including revised procedures, photographs, results of tests you have conducted, and other useful information that would assist us in evaluating your corrections. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the time within which you will do so.\n\nYour written response should be sent to:\n\nSergio Chavez, Director, Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\n1201 Harbor Bay Parkway\n\nAlameda, CA 94502\n\nRefer to Unique Identification Number CMS# 638942 when replying.\n\nIf you prefer to send your response electronically, please email it to: ORAHAFWEST5FirmResponses@fda.hhs.gov. Please include the name of your firm and CMS# 638942 number in the title of the e-mail message.\n\nIf you have any questions regarding this letter, please contact Kimberly M. Lichter, Compliance Officer, at kimberly.lichter@fda.hhs.gov or (949) 608-2967.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nDistrict Director | FDA San Francisco District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations – West Division 5\n\nCC: Bainbridge Beverage West, LLC\n\nPO Box 938\n\nColoma, MI 49038-0938","Bainbridge Beverage West, LLC","bainbridge-beverage-west-llc-638942-11282022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbainbridge-beverage-west-llc-638942-11282022","2026-10-26T08:08:00.646773+00:00","2022-12-27","638942","Ms. Sarah A. Jollay","2026-08-20T01:20:38.159+00:00","United Parcel Service","2022-11-28",{"id":160,"raw":161,"subject":63,"body_html":166,"body_text":167,"firm_name":168,"letter_id":169,"created_at":111,"fei_number":20,"letter_url":170,"updated_at":171,"action_type":23,"case_status":48,"posted_date":172,"marcs_cms_no":173,"product_type":72,"closeout_date":20,"issuing_office":62,"recipient_name":174,"body_fetched_at":175,"delivery_method":75,"recipient_title":20,"reference_number":20,"action_taken_date":176,"medical_device_id":20,"response_letter_date":20},2960,[162,163,164,62,165,13,13,13],"\u003Ctime datetime=\"2021-12-21T14:20:00Z\">12\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-03T05:00:00Z\">12\u002F03\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwestside-vapor-vapor-station-622525-12032021\">Westside Vapor \u002F Vapor Station\u003C\u002Fa>","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded ","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jason Gang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Westside Vapor \u002F Vapor Station\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8519 Navarre Road SW\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Massillon\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>44646\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@westsidevapor.com\"> info@westsidevapor.com \u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6) \u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Jason Gang:&nbsp;\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwestsidevapor.com and determined that the electronic nicotine delivery system (ENDS) products are manufactured and offered for sale or distribution to customers in the United States. &nbsp;The FDA also completed a compliance check inspection of your retail establishment on August 7, 2021. &nbsp;This Warning Letter is a notification from FDA advising you that Westside Vapor \u002F Vapor Station was observed to be in violation of federal tobacco laws and regulations. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. &nbsp;Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. &nbsp;Therefore, ENDS products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. &nbsp;These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. &nbsp;See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. &nbsp;A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). &nbsp;Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C.&nbsp;§ 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwestsidevapor.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order, including: Westside Vapor Mint\u002FIce\u002FMenthol Flavors – Peppermint and Westside Vapor Mint\u002FIce\u002FMenthol Flavors – Spearmint.&nbsp;\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. &nbsp;Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. &nbsp;In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Tobacco Product Sold to an Individual Under the Age of 21 is Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, on August 7, 2021, an inspector representing the FDA completed an inspection of your establishment located at 8519 Navarre Road SW, Massillon, OH 44646. &nbsp;During this inspection, the establishment was in violation because you or your employee sold an ENDS product to a person under 21 years of age.&nbsp;\u003C\u002Fp>\n\n\u003Cp>The violation observed during the August 7, 2021, inspection includes the following:&nbsp;\u003C\u002Fp>\n\n\u003Cp>1.&nbsp;&nbsp; &nbsp;A person under 21 years of age was able to buy a Hyde Aloe Grape ENDS product on August 7, 2021, at approximately 11:36 AM in the establishment.&nbsp;\u003C\u002Fp>\n\n\u003Cp>It is unlawful for any retailer to sell a tobacco product to any person younger than 21 years of age. &nbsp;Doing so violates Section 906(d)(5) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>The listed violation causes your ENDS product to be “misbranded” under Section 903 of the FD&amp;C Act (21 U.S.C. § 387c). &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your firm is a retailer and registered manufacturer with over 380 products listed with FDA. &nbsp;FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0001038 on September 5, 2020. However, FDA issued a negative action for PMTA STN PM0001038 in the form of a Marketing Denial Order determination on September 9, 2021, which covers 313 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by PMTA STN PM0001038 that resulted in a Marketing Denial Order determination, are adulterated and misbranded.&nbsp;\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. &nbsp;Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market. &nbsp;&nbsp;\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. &nbsp;Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. &nbsp;However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. &nbsp;Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>We will periodically inspect your establishment and review your promotional activities (e.g., website(s)) related to FDA-regulated tobacco products to assess your compliance with all applicable laws and regulations, including access, marketing, labeling, and advertising restrictions. &nbsp;\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. Please note that this warning letter does not constitute final agency action, but if you have evidence or information that you believe demonstrates that this notice was issued in error, you should also preserve any evidence or information relevant to this warning letter in the event FDA initiates regulatory action at a later date. &nbsp;This letter notifies you of our findings and provides you with an opportunity to address them. &nbsp;You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference numbers, RW2101693 and 21OH028515, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:&nbsp;\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov. &nbsp; &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002Fs\u002F &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement&nbsp;\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nVIA UPS and Electronic Mail&nbsp;\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Vapor Station\u003Cbr>\nAttn: James Jarvis\u003Cbr>\n144 N. Hamilton Rd.\u003Cbr>\nGahanna, OH 43230\u003C\u002Fp>\n\n\u003Cp>Akron Vaporstation\u003Cbr>\nAttn: Jason Gang\u003Cbr>\n1360 S Cleveland Massillon Rd\u003Cbr>\nCopley, OH 44321\u003C\u002Fp>\n\n\u003Cp>Canal Winchester Vapor Station\u003Cbr>\nAttn: Jason Gang\u003Cbr>\n6286 Gender Rd\u003Cbr>\nCanal Winchester, OH 43110\u003C\u002Fp>\n\n\u003Cp>Chillicothe Vapor Station&nbsp;\u003Cbr>\nAttn: Jason Gang\u003Cbr>\n1534 N Bridge St\u003Cbr>\nChillicothe, OH 45601\u003C\u002Fp>\n\n\u003Cp>Hartville Vaporstation\u003Cbr>\nAttn: Jason Gang\u003Cbr>\n839 W Maple St\u003Cbr>\nHartville, OH 44632\u003C\u002Fp>\n\n\u003Cp>Alliance Vapor Station\u003Cbr>\nAttn: Jason Gang\u003Cbr>\n640 W State St\u003Cbr>\nAlliance, OH 44601\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Canton Vapor Station\u003Cbr>\nAttn: Jason Gang\u003Cbr>\n2850 Whipple Ave Nw\u003Cbr>\nCanton, OH 44708\u003C\u002Fp>\n\n\u003Cp>Pataskala Vaporstation\u003Cbr>\nAttn: Jason Gang\u003Cbr>\n588 E Broad St\u003Cbr>\nEtna, OH 43062\u003C\u002Fp>\n\n\u003Cp>Attn: Gerri L Jarvis\u003Cbr>\ngljarvis02@msn.com\u003C\u002Fp>\n\n\u003Cp>Domains By Proxy, LLC\u003Cbr>\nWESTSIDEVAPOR.COM@domainsbyproxy.com&nbsp;\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com&nbsp;\u003C\u002Fp>\n\n\u003Cp>Liquid Web, L.L.C\u003Cbr>\nabuse@liquidweb.com&nbsp;\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJason Gang\n\nWestside Vapor \u002F Vapor Station\n\n8519 Navarre Road SW\n\nMassillon, OH 44646\n\nUnited States\n\ninfo@westsidevapor.com\n\n(b)(6)\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Jason Gang:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwestsidevapor.com and determined that the electronic nicotine delivery system (ENDS) products are manufactured and offered for sale or distribution to customers in the United States. The FDA also completed a compliance check inspection of your retail establishment on August 7, 2021. This Warning Letter is a notification from FDA advising you that Westside Vapor \u002F Vapor Station was observed to be in violation of federal tobacco laws and regulations.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, ENDS products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwestsidevapor.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order, including: Westside Vapor Mint\u002FIce\u002FMenthol Flavors – Peppermint and Westside Vapor Mint\u002FIce\u002FMenthol Flavors – Spearmint.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nTobacco Product Sold to an Individual Under the Age of 21 is Misbranded\n\nIn addition, on August 7, 2021, an inspector representing the FDA completed an inspection of your establishment located at 8519 Navarre Road SW, Massillon, OH 44646. During this inspection, the establishment was in violation because you or your employee sold an ENDS product to a person under 21 years of age.\n\nThe violation observed during the August 7, 2021, inspection includes the following:\n\n1. A person under 21 years of age was able to buy a Hyde Aloe Grape ENDS product on August 7, 2021, at approximately 11:36 AM in the establishment.\n\nIt is unlawful for any retailer to sell a tobacco product to any person younger than 21 years of age. Doing so violates Section 906(d)(5) of the FD&C Act.\n\nThe listed violation causes your ENDS product to be “misbranded” under Section 903 of the FD&C Act (21 U.S.C. § 387c).\n\nConclusion and Requested Actions\n\nYour firm is a retailer and registered manufacturer with over 380 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA) assigned STN PM0001038 on September 5, 2020. However, FDA issued a negative action for PMTA STN PM0001038 in the form of a Marketing Denial Order determination on September 9, 2021, which covers 313 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by PMTA STN PM0001038 that resulted in a Marketing Denial Order determination, are adulterated and misbranded.\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nWe will periodically inspect your establishment and review your promotional activities (e.g., website(s)) related to FDA-regulated tobacco products to assess your compliance with all applicable laws and regulations, including access, marketing, labeling, and advertising restrictions.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. Please note that this warning letter does not constitute final agency action, but if you have evidence or information that you believe demonstrates that this notice was issued in error, you should also preserve any evidence or information relevant to this warning letter in the event FDA initiates regulatory action at a later date. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference numbers, RW2101693 and 21OH028515, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002Fs\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nVapor Station\n\nAttn: James Jarvis\n\n144 N. Hamilton Rd.\n\nGahanna, OH 43230\n\nAkron Vaporstation\n\nAttn: Jason Gang\n\n1360 S Cleveland Massillon Rd\n\nCopley, OH 44321\n\nCanal Winchester Vapor Station\n\nAttn: Jason Gang\n\n6286 Gender Rd\n\nCanal Winchester, OH 43110\n\nChillicothe Vapor Station\n\nAttn: Jason Gang\n\n1534 N Bridge St\n\nChillicothe, OH 45601\n\nHartville Vaporstation\n\nAttn: Jason Gang\n\n839 W Maple St\n\nHartville, OH 44632\n\nAlliance Vapor Station\n\nAttn: Jason Gang\n\n640 W State St\n\nAlliance, OH 44601\n\n(b)(6)\n\nCanton Vapor Station\n\nAttn: Jason Gang\n\n2850 Whipple Ave Nw\n\nCanton, OH 44708\n\nPataskala Vaporstation\n\nAttn: Jason Gang\n\n588 E Broad St\n\nEtna, OH 43062\n\nAttn: Gerri L Jarvis\n\ngljarvis02@msn.com\n\nDomains By Proxy, LLC\n\nWESTSIDEVAPOR.COM@domainsbyproxy.com\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nLiquid Web, L.L.C\n\nabuse@liquidweb.com","Westside Vapor \u002F Vapor Station","westside-vapor-vapor-station-622525-12032021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fwestside-vapor-vapor-station-622525-12032021","2026-10-26T08:10:31.338247+00:00","2021-12-21","622525","Jason Gang","2026-08-20T02:19:23.917+00:00","2021-12-03",8,{"510k":179,"classification":180,"enforcement":181,"event":182,"event_backfill":183,"pma":184,"warning_letter":185},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]